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ABSTRACT
ELUCIDATING CELLULAR SIGNALING PATHWAYS THAT CONTRIBUTE
TO THE IMMUNOPATHOGENESIS OF APLASTIC ANEMIA
SEPTEMBER 2014
CHRISTINA ARIETA KUKSIN, B.A., UNIVERSITY OF MASSACHUSETTS
AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Lisa M. Minter

Aplastic Anemia (AA) is a rare bone marrow failure disease that is hallmarked by
hypocellular bone marrow and peripheral pancytopenia. Studies have shown that the
disease is driven by aberrant T helper type-1 (Th1) responses that destroy bone marrow
stem and progenitor cells. Although 70% of patients respond to therapy, others are
refractory or relapse after initial treatment and eventually succumb to disease. In an effort
to discover other therapeutic modalities for non-responsive patients, we sought to
elucidate signaling pathways within T cells that could be contributing to the
immunopathogenesis of AA. Using a mouse model of disease, our lab has previously
shown that both the Notch1 signaling pathway and PKCθ signaling pathway is necessary
for AA development. In this work, we expand our knowledge of both pathways and show
that active PKCθ (pPKCθ) is highly expressed in AA mice compared to irradiation
controls and active PKCθ is needed for Notch1IC activation and IFNγ production in T
cells. Also, we found that PKCθ differentially regulates Notch1IC and IFNγ in CD8+ T
cells compared to CD4+ T cells. Also, pPKCθ is highly expressed in peripheral blood
mononuclear cells collected from treatment-naïve AA patients and treating patient
vii	
  

	
  
samples with the PKCθ inhibitor, rottlerin, reduced both NOTCH1IC expression and
IFNγ production.
Furthermore, we were able to show that NF-κB signaling was necessary to drive
AA through multiple pathways. For example, we were able to decrease T cell activation
and expansion and Th1 cytokine production in our mouse model when we blocked NFκB signaling. We were also able to show that NF-κB signaling regulates CXCR4
expression, and AA induced mice have higher levels of CXCR4 present on their T cells.
Surprisingly, we were further able to reduce CXCR4 expression and motility in response
to its chemokine ligand, SDF-1 by blocking NF-κB signaling.
Finally, we were able to delineate a role for the microRNA, miR-155 in our
mouse model of AA. We found that miR-155 expression was increased in AA induced
mice, and its inhibition was able to ameliorate disease symptoms and ablate infiltration of
T cells into the bone marrow. We identified a potential target of miR-155 in CD4+ T cells
called programmed death ligand 1 (PD-L1) and show that mice induced with miR-155deficient cells have increased iTregs in the bone marrow and spleen. Taken together,
these data illuminate multiple pathways that contribute to AA which could be further
investigated for alternative treatments of the disease.
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CHAPTER 1
INTRODUCTION

1.1 T Cell Function and Immunity

1.1.1 T Cell Activation
	
  
Successful activation of naïve T cells occurs through a two-step signaling process.
The first signal is provided by antigen presenting cells (APCs) that present foreign
peptide or antigen loaded on Major Histocompatibility Complexes (MHC) to the T cell
receptor (TCR; reviewed in Smith-Garvin et al., 2009). The second signal is provided by
engagement of the co-stimulatory receptor, CD28, which is expressed on T cells
(reviewed in Bour-Jordan et al., 2011). CD28 will bind to its ligands CD80 and CD86
(also known as B7.1 and B7.2, respectively) on the APCs to induce a positive activation
signal. Both signals are imperative for successful T cell activation; without both signals,
T cells can become anergic to protect against aberrant T cell signaling. T cell signaling
can also be dampened through negative co-stimulatory molecules such as CTLA-4 and
PD-1 which can compete with CD28 for binding to CD80 and CD86 to block T cell
activation (Parry et al., 2005).
After successful ligation of the TCR, a cascade of phosphorylation events on the
activating ITAM motifs causes the recruitment of proteins to the TCR to form the
immunological synapse (Reth, 1989). The immunological synapse is characterized by
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controlled movement of membrane receptors to specific subcellular sites to facilitate
interaction with ligands on interacting cells (Yokosuka and Saito, 2010). The movement
of the IS through the lipid bilayers of the membrane also facilitates the recruitment of
important cytosolic adaptor proteins that mediate the signaling downstream of the TCR,
such as LCK and Zap-70. Additionally, the recruitment of Zap70 to the TCR further
recruits other adaptor signaling molecules, such as LAT and SLP76 (Bubeck Wardenburg
et al., 1996; Zhang et al., 1998). The formation of the immunological synapse allows for
the activation and expression of key transcription factors important in T cell survival:
activated protein-1 (AP-1), nuclear factor of activated T cells (NFAT) and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB). It is through these pathways
that expression of key survival proteins, like the T cell survival cytokine IL-2, can be
expressed. An overview of TCR signaling can be found in Figure 1.1.

1.1.2 T Cell Differentiation and Subsets

CD4+ T cells have the ability to express and produce different cytokine signatures
needed to mediate defense against different pathogens through a process called T cell
differentiation. CD4+ T cells can differentiate into many different T helper (Th) type
subset depending on the cytokine milieu present during their activation (these include:
Th1, Th2, Th17, iTreg, Th9, Th22, and Tfh). T helper type 1 (Th1) cells are responsible
for protection against intracellular pathogens such as viruses and activate CD8+ cytotoxic
T cells. Th1 cells express the lineage-specific transcription factor, T-BET, and secrete
the Th1 associated cytokine, IFN-γ (Szabo et al., 2002). T helper type 2 (Th2) cells are
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required for humoral immunity and are responsible for allergic reactions and removal of
extracellular pathogens. Th2 cells secrete IL-4, IL-5, and IL-13, and require GATA3
expression for differentiation (Zheng and Flavell, 1997). T helper-17 (Th17) cells
provide protection against nematodes and fungal infections, require TGFβ and IL-6 for
generation, secrete IL-17 and IL-23, and express RORγt (Langrish et al., 2005; Yang et
al., 2008). Th17 cells also are one of the major cell types that mediate the autoimmune
disease multiple sclerosis (Jager et al., 2009). Inducible T regulatory cells (iTregs) are
regulated by the transcription factor FOXP3 and produce TGFβ (Chen et al., 2003; Fu et
al., 2004; Rao et al., 2005). These cells, unlike their counterparts, are responsible for
suppressing inflammation.
Cytotoxic T lymphocytes (CTL) are CD8+ T cells that are activated similarly to
CD4+ T cells, except they are presented antigen through MHC type I complexes (present
on most nucleated cell types) instead of MHC type II complexes (present only on
professional APCs). This gives CTLs the unique ability to identify intracellularly infected
cells and induce programmed death pathways to reduce the spread of infection. CTLs
induce apoptosis of target cells most often through the release of lytic granules, such as
perforin and granzyme, (reviewed in Barry and Bleackley, 2002). Perforin is a pore
forming protein that is found in the cytolytic granules released from CTLs. Although its
exact function in inducing cell death is debatable, studies in perforin knockout mice have
shown that it is required to facilitate granzyme mediated killing (Kagi et al., 1994;
Kojima et al., 1994; Lowin et al., 1994). Granzyme proteins are a family of distinct serine
proteases that are found in cytolytic granules released from CTLs and activate cell death
pathways. The most common of these proteins is granzyme B, which mediates killing
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through activation of caspase pathways and DNA fragmentation (Heusel et al., 1994).
Granzyme B is important for efficient cell death, as CTLs deficient in granzyme B kill at
a slower rate (Pardo et al., 2004). Although lytic proteins released in granules are the
most common form of CTL killing, CTLs have been shown to induce death through the
Fas/Fas ligand pathway and through the production of cytokines such as IFNγ and TNF,
that can cause cell toxicity to neighboring cells. Figure 1.2 outlines the different T helper
subtypes and cytotoxic T cells.

1.1.3 T Helper Type 1 Driven Autoimmunity

Despite the extensive regulation of immune responses to protect against aberrant
reactions, clones of T or B cells that recognize self-antigens as foreign do arise and cause
autoimmunity. Some autoimmune diseases are mediated by auto-antibodies (such as
systemic lupus erythematosus); however, other autoimmune reactions are driven by selfreactive T cells that become activated, instead of tolerized or anergic, in response to selfantigen. This leads to the production of cytokines and cellular lysis pathways that cause
extreme damage in the affected organ or tissues that express the self-antigen. Some
autoimmune disease with a strong T helper type 1 component include rheumatoid
arthritis, multiple sclerosis, insulin-dependent diabetes mellitus, and aplastic anemia.
Research into the inciting antigens and mechanisms driving these diseases can help in the
development of more effective therapies.
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1.2 Aplastic Anemia
	
  
1.2.1 Symptoms and Etiologies

Severe aplastic anemia (AA) is a rare bone marrow failure disease that mainly
affects children and young adults (Young et al., 2008). At the time of diagnosis, patients
often present with low levels of circulating platelets, low white and red blood cell counts
in the periphery, and a characteristic hypocellular bone marrow. Because of the severe
pancytopenia associated with the disease, patients experience cachexia, hypoxia, are
highly susceptible to bleeding episodes, and are often vulnerable to multiple infections.
Additionally, patients with AA will often times either have coexisting or co-evolving
hematological diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) or
myelodysplasia (MDS; Young et al., 2008). If left untreated, AA is uniformly fatal
(Dezern and Brodsky, 2011).
The etiology of aplastic anemia is unclear in many cases. Paul Ehrlich first
described AA in 1888 in a pregnant woman, and while no strong correlation exists, some
cases of AA have developed after pregnancy especially after episodes of eosinophilic
fasciitis (Choudhry et al., 2002; Young, 2006). While five to ten percent of AA cases
follow an episode of seronegative hepatitis (Lu et al., 2004), no definitive infectious
agent has been shown to cause disease. Some cases are associated with chemical or drug
exposure, such as benzene, pesticides, and chloramphenicol; overrepresentation of drug
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metabolizing glutathione-S-transferase gene deletions have been observed in some
patient cohorts (Dufour et al., 2005; Sutton et al., 2004; Young et al., 2008).
One third of aplastic anemia patients have shortened telomeres in their white
blood cells (Young, 2006). Upon closer assessment of genomic DNA, some patients,
even older adults, were shown to have mutations in TERC (Fogarty et al., 2003), TERT
(Yamaguchi et al., 2005), and TERF1 (Savage et al., 2006). Family members who share
these mutations but have adequate blood counts, do have shortened telomeres, but also
have hypocellular bone marrows and reduced CD34 population (Fogarty et al., 2003).
Based on these findings, it seems that mutations in genes that encode proteins that repair
telomeres confers a genetic risk factor to patients since hematopoietic stem cells with
already-shortened telomeres may not be able to withstand the immune mediated damage
associated with disease (Young, 2006). Despite evidence of some etiological correlation,
the cause of AA is still unknown in most cases.

1.2.2 Evidence for Aplastic Anemia as an Autoimmune Disease

Because many cases of AA are idiopathic, it has been hard to properly study the
underlying mechanisms that contribute to the early pathogenesis of the disease.
However, evidence points to an inciting self-immune reaction as the driving impetus of
disease development. It has been shown in early cases that conditioning regimens to
dampen the immune system before bone marrow transplants were critical even when
recipients received syngeneic bone marrow (Appelbaum et al., 1985; Hinterberger et al.,
1997). However, the most compelling evidence that AA is an immune mediated disease
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is the responsiveness of patients to immunosuppressive therapies such as anti-thymocyte
globulin (ATG) and cyclosporin A (CsA; Young, 2006). Some patients are refractory to
immunosuppressive therapies, and this information could infer a non-immune modality
of disease. However, these patients characteristically present with severe stem cell
depletion, a “spent” immune response, or immunological mechanisms causing the
resistance to immunosuppressive therapies (Young et al., 2008).
Because of the strong immune mechanism associated with AA and the idiopathic
nature of the disease, AA has been characterized as an autoimmune bone marrow failure
disease. Because of this, there has been a search for the inciting autoantigens responsible
for disease. There have been a few autoantigens identified by screening patient blood
samples against a peptide library. One study identified kinectin, a widely expressed
protein that is highly expressed by hematopoietic cells in the bone marrow, being bound
by autoantibodies from 40% of patient sera. Although kinectin-reactive cytotoxic T cells
can be generated in vitro to inhibit hematopoietic colony formation, no anti-kinectin T
cells can be found in patients peripheral blood or bone marrow samples (Hirano et al.,
2003). Another autoantigen found in a minority of patients was diazepam-binding related
protein-1, an enzyme essential in the oxidation of unsaturated fatty acids that is broadly
distributed in tissues. Unlike kinectin, a putative T-cell epitope derived from diazepambinding related protein-1 could stimulate one patient’s cytotoxic T cells (Feng et al.,
2004). A few other hematopoietic associated proteins (and not stromal associated
proteins) have been identified as targets of autoantibodies in AA patients using
serological identification of antigens by recombinant cDNA expression cloning
(SEREX), however it is still unclear as to how identifying these autoantibodies can be
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used theraputically, and how the targets of the autoantibodies may correlate to the T cellmediated pathogenesis of AA (Goto et al., 2013).

1.2.3 Immunopathogenesis of the Bone Marrow

The severe pancytopenia associated with AA is the result of an extreme defect in
hematopoiesis in the hypocellular bone marrow of patients. At first it was believed that
there was a defect solely in the patients’ hematopoietic stem cells that caused this
pancytopenia. However, early in vitro analysis of patient bone marrow showed that T
cells mediated the pathogenicity in the bone marrow and limited the colony formation in
a clonogenic assay. When lymphocytes were depleted from diseased bone marrow,
colony formation was restored. Addition of the AA lymphocytes to normal bone marrow
samples inhibited hematopoiesis (Gorski et al., 1979; Kagan et al., 1976; Torok-Storb et
al., 1980). Early assessment of the suppressive lymphocytes characterized them as
primarily activated cytotoxic T cells (Maciejewski et al., 1994). Molecular analysis of
patients’ CD8+CD28- cells using flow cytometric analysis for T cell receptor (TCR) Vβ
subfamilies length and sequencing analysis of the CDR3 region show an oligoclonal
expansion of CD8+CD28- cells upon disease diagnosis, depletion of these clones with
immunosuppressive treatment, and re-emergence of the clones upon relapse (Risitano et
al., 2004). It is unclear how these T cells are activated; however, overrepresentation of
HLA-DR2, an MHC Class II molecule which is also highly expressed in multiple
sclerosis patients, suggests a role for antigen recognition by T cells (Maciejewski et al.,
2001; Nakao et al., 1994).
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Further analysis of circulating T cells from AA patients point to a Th1 mechanism
driving disease. Early studies described the pathogenic lymphocytes as producing T
helper type-1 cytokines, such as IFNγ and TNF (Sloand et al., 2002; Tong et al., 1991;
Zoumbos et al., 1985). Polymorphisms in the tumor necrosis factor-α (TNF2) promoter at
−308 (Demeter et al., 2002), IFNγ (Dufour et al., 2004), and in IL-6 genes (Gidvani et
al., 2007) are prevalent in patient cohorts. Additionally, AA patient T cells have
increased levels of the Th1 master regulator transcription factor T-BET (Solomou et al.,
2006), as well as intracellular NOTCH1, which directly regulates T-BET expression
(Roderick et al., 2013). The regulatory T cell population, whose purpose is to suppress
autoreactive T cells, is decreased in patients with aplastic anemia (Solomou et al., 2007)
and studies using animal models of AA have been able to ameliorate disease with an
infusion of regulatory T cells (Chen et al., 2007).
The mechanism by which the cytotoxic T cells mediate destruction of the
hematopoietic stems cells of the bone marrow is through different apoptosis-inducing
pathways. Bystander death of the hematopoietic stem cells and stromal cells is caused by
the high levels of cytokines expressed in the bone marrow which inhibits the ability of
the cells to proliferate and differentiate, and causes them to upregulate the Fas receptor
(Maciejewski et al., 1995a; Maciejewski et al., 1995b; Selleri et al., 1996). Because of the
upregulation of the Fas receptor on the hematopoietic stem cells of the bone marrow,
direct T cell mediated killing through Fas/Fas ligand interactions has been documented
(Ismail et al., 2001; Killick et al., 2000; Maciejewski et al., 1995b). Cytotoxic T cellmediated killing also directly mediates destruction of the hematopoietic and stromal cells
of the bone marrow through the release of the cytotoxic granules, perforin and granzyme,
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which are upregulated in patients with aplastic anemia (Kook et al., 2001; Xu et al.,
2003). An overview of the immunopathogenesis of the bone marrow in AA can be found
in Figure 1.3.

1.2.4 Current Treatments

Currently, there are three types of treatment for Aplastic Anemia: hematopoietic
stem cell transplantation (HSCT), immunosuppressive therapy (IST), and supportive care.
In children, the most effective treatment for AA is HSCT using bone marrow from a
histocompatible matched sibling donor as the source for hematopoietic stem cells
(Scheinberg, 2012). A retrospective study done by the Center for International Blood and
Marrow Transplant Research (CIBMTR), reported a 5 years survival rate of 82% for
those under 20 years of age, compared with approximately 50% for those over the age of
40 (Gupta et al., 2010). Because of the rising risk of graft-versus-host disease (GVHD)
and other mortality associated risks with older patients, 40 is the upper age limit for
HSCT in the clinic (Maury et al., 2009; Peinemann et al., 2011).
For patients with no available HSCT donor, or for patients over the age of 40, the
best mode of treatment is immunosuppressive therapy (IST). The standard IST for
patients in the United States, Europe and Japan is administration of horse ATG and CsA,
which produces positive hematologic responses in 60%-75% of cases (Young, 2006).
Children have a higher survival rate with IST than adults (75% vs. 50%; Scheinberg,
2012). IST is routinely continued for 6 months, at which point efficacy of treatment and
alternate treatment modalities are explored if there is IST failure.
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For patients who are refractory to the initial HSCT or IST treatments, there are
additional options. For patients without a matched sibling donor, there has been an
increase in unmatched donor HSCT, with considerable success in children (Scheinberg,
2012). In patients for whom HSCT is not a preferable option, a small study reported
some success with a second round of IST using rabbit ATG, rather than horse ATG, or
Alemtuzumab, a monoclonal antibody specific for the mature lymphocyte antigen, CD52,
with Alemtuzumab being better-tolerated than rabbit ATG (Risitano et al., 2010). In
patients who relapse after initial successful IST treatment, a common practice is to
reintroduce CsA for a period of 2 to 3 months, and taper off treatment to low doses
(Scheinberg and Young, 2012).
Supportive care is important in the treatment of AA and, although not curative, it
is essential to the management of disease symptoms. Red blood cell (RBC) or platelet
transfusions are often necessary to maintain quality of life; however, the risk of
alloimmunization to RBC antigens or HLA antigens is a considerable risk. Restrictive
transfusion policies for those who are candidates for HSCT is required (Hochsmann et
al., 2013). Patients who have been given numerous RBC transfusions are also at risk for
an iron overload. Therefore, iron chelation therapy is needed.
Because of a severely suppressed immune system, prevention of infection in AA
patients is paramount. Neutropenia is extremely common in AA patients, leaving them
susceptible to infection, especially fungal infections. Therefore, many patients are given
prophylactic antibiotic or anitmycotic drugs. Although viral infections can be severe in
immunosuppressed patients, prophylactic antiviral drugs are not widely used; therefore,
patients must be monitored closely for signs of infection.
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1.3 Protein Kinase C Theta in T Cells
	
  
1.3.1 Protein Kinase C Family

Members of the protein kinase C (PKC) family are serine and threonine kinases
that phosphorylate numerous target proteins in the cell. This family of 10 isozymes is
divided into three groups depending on the homology of their structure and mode of
activation. The members of the conventional PKC group (cPKC) consist of PKC-α,
PKC-βI, PKC-βII, and PKC-γ. cPKC members are activated by Ca2+ and diacylglycerol
(DAG). The novel PKC (nPKC) family consists of PKC-δ, PKC −ε, PKC −η and PKC θ and are activated by DAG or PMA alone because they lack the critical Ca2+ binding
motifs in their C2 domain. The atypical PKC (aPKC) family contains PKC -ζ and PKCι/λ and are not activated by DAG/PMA or calcium. They lack a calcium-sensitive C2
domain, while their C1 domain binds PIP3 or ceramide (not DAG or PMA).
PKCθ shares a similar conformation to members of the nPKC family (shown in Figure
1.4A) with the N-terminus of PKCθ comprising the regulatory region while the Cterminus of the protein comprises the catalytic region (Baier et al., 1993; Chang et al.,
1993). As explained above, the C2 domain of PKCθ is similar to other PKC family
members, however, it does not bind Ca2+. The two tandem cysteine-rich domains of C1
bind to DAG, with the C1b domain having a higher affinity for DAG than C1a (Melowic
et al., 2007). The C1 domain is flanked by two variable regions, V1 and V3. V3 has
been shown to be involved in an indirect association of PKCθ with CD28, probably
through interaction with LCK (lymphocyte-specific protein tyrosine kinase). This
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interaction leads to the translocation of PKCθ to the immunological synapse in T cells
(Kong et al., 2011).
When PKCθ is its inactive state, the N-terminal regulatory region binds to the
substrate binding region in the catalytic domain on the C terminus and blocks the
interaction of the catalytic domain with its substrates (House and Kemp, 1987). PKCθ
becomes activated through a two step process (Seco et al., 2012). After activation of the
T cell through the TCR and CD28 stimulation, DAG binds to the C1 domain to ‘open’
the activation loop (Melowic et al., 2007). After exposure of the activation loop, PKCθ
can be phosphorylated by germinal center kinase-like kinase (GLK) on Thr538 in the
activation loop, which results in catalytic activation (Chuang et al., 2011). PKCθ is
phosphorylated at six sites: Y90, T219, T538, S676, S685, and S695, which are important
for activation and downstream signaling (reviewed in Wang et al., 2012).

1.3.2 The Role of PKCθ in T Cell Activation

When T cells are stimulated through the TCR and CD28 co-receptor, the
immunological synapse is generated at the area of contact between the T cell and APC
(Rao et al., 1999). Part of the synapse is called the supramolecular activation complex
(SMAC) which includes different signaling molecules important to T cell signaling, such
as LCK. After successful T effector cell stimulation, PKCθ is recruited to the SMAC
through association with the cytoplasmic tail of CD28 (Kong et al., 2011; Schaefer et al.,
2004). In the SMAC, PKCθ is phosphorylated by LCK at Y90 which allows for its
subsequent phosphorylation and autophosphorylation at T219 (Bauer et al., 2001; Bi et
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al., 2001; Freeley et al., 2005; Lee et al., 2005; Liu et al., 2002; Liu et al., 2000; Thuille
et al., 2005). Phosphorylation is necessary for retaining PKCθ in the IS, and without
PKCθ, IS formation cannot be sustained, thus blocking successful T effector cell
signaling (Valitutti et al., 1995). In T regulatory cells, however, PKCθ is sequestered
away from the IS in the distal pole complex, suggesting differential roles for PKCθ in T
effector cells and T regulatory cells (Zanin-Zhorov et al., 2010).
After activation of PKCθ through phosphorylation at T538 by GLK, PKCθ can
mediate downstream T cell signaling (Chuang et al., 2011). PKCθ phosphorylates the
membrane-associated guanylate kinase, Carma1, also known as Card11 (Blonska and
Lin, 2009). Phosphorylation of Carma1 induces the formation of the CBM complex, a
scaffolding complex comprised of Carma1, Bcl10 and Malt1, which activates the NF-κB
signaling pathway (Thome and Weil, 2007). PKCθ also activates the AP1 transcription
factor by phosphorylation of the ste20-family kinase SPAK and is important for NFAT
transactivation (Li et al., 2004; Pfeifhofer et al., 2003).
To further explore the role of PKCθ in T cell signaling, knockout mice were
developed by replacing the exon encoding the ATP-binding site of the kinase domain
with the neomycin resistance gene (Sun et al., 2000). Using these mice, it was shown that
that PKCθ-/- CD3+ T lymphocytes have a severe reduction in proliferation and IL-2
secretion (Sun et al., 2000). Based on this evidence, PKCθ is an integral driver of T cell
activation, and Figure 1.4B summarizes its role in T cell activation.
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1.3.3 The Role of PKCθ in Disease and Autoimmunity

How PKCθ may contribute to T helper cell-mediated processes remains
controversial. Reports suggest PKCθ is required for Th2 and Th17 responses, but it has
been shown to be dispensable for generating both Th1-mediated antiviral and memory T
cell responses (Kwon et al., 2012; Marsland et al., 2005; Marsland et al., 2004).
Accumulating evidence supports a function for PKCθ in mediating autoimmune
disorders, such as experimental autoimmune encephalomyelitis, rheumatoid arthritis, and
myosin-induced autoimmune myocarditis (Healy et al., 2006; Marsland et al., 2007;
Salek-Ardakani et al., 2005; Tan et al., 2006). Furthermore, in a mouse model of graftversus-host disease (GVHD), which has a strong Th1 component, PKCθ was required to
induce GVHD pathology, but not to clear viral pathogens or mediation of graft-versusleukemia processes (Valenzuela et al., 2009). These data suggest that inhibiting PKCθ in
T cells may abrogate their allopathogenic activity, while preserving their ability to
respond appropriately to infectious stimuli. As such, PKCθ may represent an attractive
target for modulating immune-mediated conditions, including autoimmune diseases.

1.4 Notch Signaling Pathway

1.4.1 Notch Receptors and Their Ligands

The Notch protein was originally discovered in Drosophila melanogaster in 1914
when deletion of the gene encoding this protein produced a “notched” wing phenotype.
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Since the discovery of Notch, it has become evident that it is plays a pivotal role in cell
fate decisions throughout different systems. Mammals express four Notch receptors
(Notch1, 2, 3, and 4) and their differing structures are summarized in Figure 1.5A. Notch
contains three major domains: the extracellular domain of Notch is comprised of
epidermal growth factor (EGF)-like repeats, the transmembrane domain contains a
cysteine rich lineage domain (LIN) and a hetero-dimerization domain which prevents
ligand-independent activation, and an intracellular domain. The intracellular domain
contains a RAM domain (RBP-Jκ-associated molecule domain), an ANK domain
(ankyrin repeat domain) that mediates protein-protein interactions, two nuclear
localization sequences (NLS), a transcriptional activation domain (TAD; only present in
Notch1 and Notch2), and a PEST domain (proline-glutamate-serine and threonine-rich
domain (PEST) that regulates protein stability (Osborne and Minter, 2007).
Notch can be activated by association with its ligands: Delta-like (DLL1, DLL3,
and DLL4) and Jagged (Jag1 and Jag2) ligands (Figure 1.5A). All Notch ligands contain
a conserved DSL sequence (Delta/Serrate/Lag2), which is important for receptor binding,
and EGF-like repeats. Jagged ligands also contain a cysteine rich (CR) region close to the
plasma membrane. To promote ligand binding, Notch can be glycosylated on its
extracellular domain by the Fringe glycosyltransferases, Manic fringe, Lunatic fringe,
and Radical fringe . In most cases, Fringe glycosylation promotes binding by the Deltalike ligands (Radtke et al., 2010).
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1.4.2 Notch Signaling Pathway: Canonical and Non-Canonical

For activation of the Notch signaling pathway, the protein must undergo a series
of proteolytic cleavages to create its active form (intracellular Notch, or NotchIC). Notch
is produced in the Golgi, and in the trans-Golgi, it undergoes its first cleavage event by
furin-like proteases, creating a non-covalently linked, heterodimeric receptor (Logeat et
al., 1998). The heterodimeric form of Notch translocates to the plasma membrane where
it can then interact with its ligands. After ligand interaction, Notch is cleaved by an
ADAM metalloprotease, TNFα-converting enzyme (TACE), which causes the release of
the extracellular portion of the protein (Brou et al., 2000). Notch is then endocytosed and
the intracellular portion of the protein is ubiquitinated, allowing for the final cleavage of
Notch by γ-secretase (De Strooper et al., 1999). This final cleavage releases Notch from
the membrane and allows for its signaling within the cytoplasm and the nucleus.
The canonical signaling pathway of Notch results in gene transcription through
interaction with its binding partner RBP-Jκ (murine homolog), also called as CSL (CBF1 in mammals, suppressor of hairless in Drosophila melanogaster and Lag 1 in
Caenorhabditis elegans). RBP-Jκ exists in the nucleus as a transcriptional repressor;
however, binding of NotchIC to RBP-Jκ results in the recruitment of co-activators, such as
p300 and MAML (Mastermind-like). The building of this complex leads to transcription
of Notch target genes, such as Hes (Hairy/enhancer-of-split) or Hey (Hairy/enhancer-ofsplit related).
Lately, there have been descriptions of transcription of Notch genes that do not
require RBP-Jκ, and this has become known as non-canonical Notch signaling. It has
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been shown previously that Notch and NF-ĸB exist in a complex on the Ifng promoter
even in the absence of RBP-Jκ (Cho et al., 2009; Shin et al., 2006). Also, T cell activation
and differentiation was found to be Notch1 and NF-ĸB dependent, but RBP-Jκ
independent (Dongre et al., 2014). Interestingly, NF-ĸB binding sites on DNA contain a
nested RBP-Jκ consensus binding sequence. (Minter and Osborne, 2012). Other than NFĸB mediated Notch signaling, other binding partners have been described in Notch
signaling that are independent of RBP-Jκ, such as PI3K, Akt, T-bet and GATA-3. These
signaling events happen not just in the nucleus, but also in the cytosol (Minter and
Osborne, 2012). An outline of canonical Notch signaling is found in Figure 1.5B.

1.4.3 Notch Signaling in T Cells

Notch signaling is critical for the regulation of T cell development, activation, and
differentiation. Notch1 is required for T cell lineage commitment, and deletion of Notch
in developing thymocytes redirects them towards a B cell fate (Pui et al., 1999).
Conversely, overexpression of Notch1 in bone marrow progenitors initiates T cell
leukemia (Radtke et al., 1999). Notch signaling was also shown to be important in T cell
activation. When T cells are activated through TCR and CD28 ligation, cleaved Notch1
leads to expression of CD25 (the high affinity IL-2 receptor) and the secretion of IL-2,
while inhibition of Notch signaling using a γ-secretase inhibitor (GSI) blocks peripheral
T cell activation, proliferation, and IFN-γ production (Adler et al., 2003; Palaga et al.,
2003).
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How Notch signaling drives the differentiation of T cells towards different helper
subtypes is an area of intense investigation. Inhibition of Notch signaling using GSIs
blocks the ability of T cells to differentiate into Th1 cells (but not Th2) through a
reduction in T-bet expression (Minter et al., 2005). Using mice deficient in RBP-Jκ or
expressing a dominant negative Mastermind-like (DNMAML), it has been surmised that
Notch signaling regulates Th2 fate via GATA3 and IL-4 expression; however, since
Notch was not specifically deleted in these studies, it is unknown if other RBP-Jκ or
MAML binding partners could be driving Th2 differentiation (Amsen et al., 2007; Fang
et al., 2007). Inhibition of Notch activation using GSI has also been shown to regulate
Th17 differentiation, and Treg differentiation through regulation of FoxP3 expression
(Keerthivasan et al., 2011; Samon et al., 2008). Notch signaling has also been shown to
play an important role in CD8+ T cell signaling. Inhibition of Notch results in a decrease
in the expression of the CD8+ T cell associated transcription factor, Eomes, and thus
results in the reduction of granzyme B and perforin production (Cho et al., 2009).
Altogether, this evidence suggests that Notch signaling plays pleiotropic roles in T cell
activation and differentiation.

1.5 NF-κB Pathway

1.5.1. NF-κB Signaling Pathway

The NF-κB family of transcription factors comprises five homo- or heterodimers:
c-Rel, p65 (RelA), RelB, p50 (NF-κB1) and p52 (NF-κB2). p50 and p52 are processed
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from the precursors p105 and p100, respectively. Each homo- or heterodimer has distinct
expression patterns and regulatory functions, depending on the cell type (Gilmore, 2006).
All NF-κB subunits contain a ‘Rel homology domain’ (RHD) near the N-terminus which
contains the sequences needed to bind to DNA (κB elements), allows interaction between
the subunits and the inhibitory IκB proteins, and facilitates NF-κB entry into the nucleus.
c-Rel, p65, and RelB possess transcriptional transactivation domains (TADs), as shown in
Figure 1.6A. Usually, dimers containing these subunits are associated with active
transcription (Hoffmann et al., 2006). Control of target gene transcription by p50 or p52,
two members lacking TAD, causes repression of transcription at κB sites, either by
recruiting histone deacetylases to promoters or by blocking binding by other NF-κB
subunits that contain TADs. However, the subunits p50 or p52 can also promote gene
expression by interacting with co-activators (Hoffmann et al., 2006).
The NF-κB signaling pathway can be activated through either the canonical or
non-canonical route. In the canonical pathway, NF-κB exists in an inactive state
sequestered in the cytosol of the cell by inhibitor of κB (IκB). When the pathway is
stimulated, IκB kinase-β (IKKβ) is activated and phosphorylates IĸB causing its
subsequent ubiquitination and degradation. NF-κB is then released and translocates into
the nucleus where it can mediate transcription of downstream target genes. The
predominate subunits involved in the canonical pathway are p65 and p50 (Hayden and
Ghosh, 2008). In the non-canonical pathway, NF-κB inducing kinase (NIK) directly
phosphorylates and activates IKKα, which in turn phosphorylates p100, and causes its
processing to p52. p52 then goes on to form a heterodimer with RelB and translocate to
the nucleus to mediate gene transcription (Sun, 2011).
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1.5.2 NF-κB Signaling and T cell activation

When T cells become activated by antigen recognition through the TCR, a series
of signaling events downstream of the TCR and CD28 causes activation of PKCθ
(described above) and activation of NF-κB through the classical pathway. PKCθ
phosphorylates Carma1 at S552 and S645 early and transiently after TCR signaling, and
these phosphorylation steps are critical to induce the conformational change in Carma1
that allows the binding of Bcl10 and Malt1, to form the CBM complex (Matsumoto et al.,
2005; Sommer et al., 2005). Phosphorylation of Carma1 at a third site S649 is inhibitory
to Carma1 activation. This phosphorylation event is delayed after TCR signaling but is
sustained for a longer duration than the early phosphorylation steps (Moreno-Garcia et
al., 2009). After assembly of the CBM complex, IKKγ is polyubiquitinanted, likely by
TRAF6, while IKKβ is phosphorylated by the protein kinase, TAK1 (Thome et al., 2010;
Wang et al., 2001). Once phosphorylated, IKKβ is able to phosphorylate IκB and trigger
its proteasomal degradation, allowing NF-κB to translocate into the nucleus and mediate
downstream transcription of genes involved in T cell survival, proliferation and effector
functions. A summary of NF-κB signaling after T cell activation is shown in Figure 1.6B.
In activated T cells, NF-κB has been shown to control the expression of IL-2,
CD25, IL-2Rα, and IFNγ (Vallabhapurapu and Karin, 2009). NF-κB has also been shown
to be important in T cell differentiation. Transgenic mice which express non-degradable
IκB in T cells have impaired Th1 responses but not Th2 responses (Aronica et al., 1999).
RelA, c-Rel and RelB are needed for IFNγ production, however, only RelB deficiency
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has been shown to cause a reduction in T-bet expression (Balasubramani et al., 2010;
Corn et al., 2005; Hilliard et al., 2002). CD4+ cells with a deficiency in p50 can still
express T-bet and produce IFNγ. However, p50 has been shown to be necessary for
GATA3 expression, and p50-/- deficient mice have defective allergic airway
inflammatory responses (Das et al., 2001). c-Rel has also been shown to play a major role
in thymic and peripheral Treg differentiation and FoxP3 expression (Long et al., 2009;
Zheng et al., 2010). c-Rel- and p65-deficient T cells have defective IL-17 production and
Th17 differentiation (Ruan et al., 2011). c-Rel deficient mice are also resistant to
experimental autoimmune encephalomyelitis (Hilliard et al., 2002). Based on this
evidence, it is clear that NF-κB subunits have differential roles in T cell activation and
differentiation.

1.5.3 NF-κB in Disease

Because NF-κB is implicated in many cell survival pathways throughout different
systems, it has long been associated with disease. Its role in the proinflammatory
response, anti-apoptotic pathways, and cellular growth is prominent; therefore, its
dysregulation has been implicated in many cancer models (Baldwin, 2001). NF-κB is also
used by HIV as its transcriptional regulator to propagate new virus (Ghosh et al., 1998).
Other viruses, such as Epstein Barr virus and Herpes Simplex virus, also activate NF-κB
in an attempt to induce proliferative and pathogenic responses in their host cell
(Mosialos, 1997). Chronically activated NF-κB has been implicated in a number of
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autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, type I
diabetes, multiple sclerosis, and inflammatory bowel disease (Sun et al., 2013).
Because of its widespread involvement in disease, many attempts to target the
pathway have been studied. Many classes of drugs have been shown to block different
parts of the NF-κB pathway, such as glucocorticoids, NSAIDS, immunosuppressive
agents (such as CsA), and cyclopentenone prostaglandins (Yamamoto and Gaynor,
2001). Clinical trials are currently underway in many different diseases using broader
inhibitors that are known to target the NF-κB pathway, such as curcumin which downregulates expression of NF-κB, along with other transcription factors, to cause apoptosis,
and Bortezomib, a broad proteasome inhibitor that blocks the degradation of IκB.
Because of the wide scope of NF-κB signaling in disease, many specific inhibitors are
being developed, but they are still in early stages of study (Sun et al., 2013).

1.6 Chemokine Receptor 4

1.6.1 The CXCR4/SDF-1 signaling axis

Chemokines are small molecules that have selective chemoattractant properties
depending on the tissue microenvironment. They can have a broad range of activities
because of the multiple signaling pathways induced by the binding of chemokines to their
receptors. Chemokine receptors are seven-pass-transmembrane receptors coupled to
heterotrimeric G proteins (Viola et al., 2006) and through binding to their selective
chemokines, cells can be directed to migrate to sites of infections or to different lymphoid
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organs. Stromal derived factor-1 (SDF-1), also known as CXCL12, is the sole ligand for
CXCR4, and after the binding of SDF-1, CXCR4 undergoes dimerization to activate
signaling pathways (Percherancier et al., 2005; Vila-Coro et al., 1999). When CXCR4
becomes activated, the receptor is able to activate the heterotrimeric G-protein and
activate downstream signaling pathways important to gene transcription, actin
polymerization, cytoskeleton rearrangement and cell migration (Holland et al., 2006;
Vila-Coro et al., 1999).
CXCR4 and SDF-1 deficient mice have a lethal phenotype, showing that CXCR4
and SDF-1 are important during embryonic development. CXCR4 is expressed on
progenitor cells, and this allows for the migration of embryonic stem cell progenitors
where they will differentiate into adult organ and tissues (Wong and Korz, 2008).
CXCR4 is expressed on hematopoietic stem cells, and SDF-1 has a role in the quiescence
for long-term HSC maintenance (Sugiyama et al., 2006). The main source for SDF-1 in
the adult is the bone marrow. CXCR4 is also expressed on endothelial cells, smooth
muscle cells, and endothelial progenitor cells, and it has been shown to promote
angiogenesis (Gupta et al., 1998; Yamaguchi et al., 2003; Zernecke et al., 2005). SDF1/CXCR4 has an important role in neurogenesis, and mice deficient in both SDF-1 and
CXCR4 have abnormal development, both of the cerebellum and hippocampus (Miller et
al., 2008). In the late 1990’s, CXCR4 was shown to serve as a co-entry receptor for HIV1 on CD4+ T cells (Feng et al., 1996). CXCR4 expression has also been shown to be
overexpressed in many cancers, including human breast cancer cell lines and primary and
metastatic breast tumors, ovarian cancer, prostate cancer and melanoma (Hall and
Korach, 2003; Kim et al., 2008; Muller et al., 2001; Taichman et al., 2002).
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1.6.2 CXCR4 and T cell Signaling

CXCR4 is constitutively expressed on T lymphocytes, and CXCR4’s main role in
T cells is to drive migration along gradients of SDF-1. CXCR4 also acts as a costimulator
of T cell proliferation and T cell differentiation through interaction with the TCR (Kumar
et al., 2006; Molon et al., 2005). When SDF-1 initiates CXCR4 signaling and activates G
proteins downstream of T cell activation, there is an increase in TCR-activation
associated kinases and adaptor proteins, such as phosphatidylinositol 3-kinase, ZAP-70,
Fyn, Lyn, and SLP-76 (Chernock et al., 2001; Ganju et al., 1998; Smith et al., 2013;
Ticchioni et al., 2002). Downstream of the TCR, activation of CXCR4 also increases the
activity of Akt and the JAK/STAT signal transduction pathway (Ganju et al., 1998;
Tilton et al., 2000). Also, for CXCR4 signaling to activate Ras and the ERK pathway,
ZAP-70 expression is required (Kremer et al., 2003; Kumar et al., 2006).
Although CXCR4 depends on TCR signaling, CXCR4 engagement does not
simply recapitulate TCR signaling pathways. For example, while the TCR can stimulate
NF-κB and NFAT activity, multiple studies have proven that CXCR4 cannot (Kumar et
al., 2006; Molon et al., 2005; Nanki and Lipsky, 2000). Also, stimulation of CXCR4 with
SDF-1 does not increase the phosphorylation of the TCR or ZAP-70, suggesting that
CXCR4 utilizes pre-existing, constitutively-phosphorylated TCR-ZAP-70 complexes
(Kumar et al., 2006). Because CXCR4 activation increases ERK signaling and ERK
enhances the half-life of AP-1 subunits, CXCR4 signaling after SDF-1 binding most
likely enhances the survival of resting T cells by activating several anti-apoptotic genes
(Muller et al., 2001; Suzuki et al., 2001). Also the activation of AP-1 through CXCR4
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helps to upregulate the production of AP-1 target genes, such as CD69, IL-10, and IL-2
(D'Ambrosio et al., 1994; Jain et al., 2005; Wang et al., 2005). CXCR4 effects on IFNγ
production seem to be context dependent. If SDF-1 is added to cultures at the time of
TCR ligation using costimulatory antibodies, IFNγ production is not increased; however,
when SDF-1 is added to culture 2 hours prior to TCR ligation, or after APC-mediated T
cell stimulation, it can significantly increase IFNγ production by T cells (Kumar et al.,
2006; Molon et al., 2005; Nanki and Lipsky, 2000). Based on this evidence, it seems that
CXCR4 can be used as a costimulatory molecule to help promote T cell survival with or
without TCR signaling in environments in which SDF-1 is present. CXCR4 signaling in
T cells is summarized in Figure 1.7.

1.6.3 Therapeutic Benefits of Altering CXCR4 Signaling

As explained above, CXCR4 overexpression has been described in many primary
and metastatic cancers and other autoimmune disease, such as multiple sclerosis and
lupus (Domanska et al., 2013). Also, there have been reports of an upregulation of
CXCR4 and SDF-1 after chemotherapy with anti-angiogenic drugs such as bevacizumab,
(Kioi et al., 2010; Shaked et al., 2008). Because of this, CXCR4 inhibition has been
studied as a potential therapy for these diseases. Studies of the CXCR4 inhibitor
AMD3100 shows that it mobilizes CD34+ human hematopoietic stem and progenitor
cells from the bone marrow into the peripheral blood (Broxmeyer et al., 2005). Therefore,
AMD3100 has been approved by the FDA for stem cell mobilization into the peripheral
blood for the purposes of transplantation, and together with G-CSF (granulocyte-colony
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stimulating factor), as therapy in Non-Hodgkin’s lymphoma and multiple myeloma
patients. Currently, multiple Phase I and Phase II trials are underway to assess the
efficacy of CXCR4 inhibitors in multiple cancers (with or without corresponding
chemotherapy), and other autoimmune diseases (Domanska et al., 2013).

1.7 Interaction of Signaling Pathways in T cells

1.7.1 Cross talk between the NF-κB and PKCθ pathways

Considerable evidence has been gathered that PKCθ activation is crucial for
stimulation of the NF-κB pathway. For example, a constitutively active mutant of PKCθ
induces activation of both an NF-κB reporter gene, and activation of the CD28 response
element encoding for IL-2 (Coudronniere et al., 2000; Lin et al., 2000). While inhibitors
specific for PKCα. –β, and -γ had no effect on NF-κB nuclear translocation after T cell
stimulation, addition of rottlerin (a PKCθ and –δ specific inhibitor) to T cells was able to
abrogate NF-κB translocation (Coudronniere et al., 2000). This data was confirmed by a
study wherein expression of kinase-dead PKCθ or addition of PKCθ antisense RNA
blocked NF-κB activation after TCR stimulation (Lin et al., 2000). A loss of PKCθ in
CD4+ T cells from PKCθ deficient mice causes a severe reduction in IκB degradation and
NF-κB activation following TCR stimulation, a decrease in IL-2, and a decrease in T cell
stimulation (Sun et al., 2000). PKCθ regulation of the NF-κB pathway is limited to TCR
mediated NF-κB activation (canonical pathway), as stimulation of NF-κB by either TNF
or IL-1 (through the non-canonical pathway) is preserved (Sun et al., 2000). PKCθ
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directly interacts with the NF-κB pathway through phosphorylation of Carma1 (described
above). This action allows for formation of the CBM complex, and the subsequent
downstream events in canonical NF-κB signaling.

1.7.2 Cross talk between the Notch and NF-κB pathways

Several studies have demonstrated interaction between Notch and NF-κB
pathways in T cells. When Notch signaling is abrogated using GSI, NF-κB activity is
reduced in peripheral T cells (Palaga et al., 2003). Cytosolic Notch1IC has been shown to
physically interact with Carma1 and the nucleated CBM complex, and blocking Notch
using shRNA causes inhibition of the formation of the CBM complex (Shin et al., 2014).
Additionally, Notch has been shown to physically interact with NF-κB (specifically p50
and c-Rel), and Notch regulates NF-κB activity by sustaining its nuclear localization
(Shin et al., 2006). Also, data from our lab has shown that when a non-nuclear form of
Notch1IC was expressed, NF-κB activity remains high in T cells (Shin et al., 2014).
Furthermore, Notch3 transgenic mice show constitutive NF-κB activity in T regulatory
cells and T-ALL models (Barbarulo et al., 2011; Vacca et al., 2006). As mentioned
above, chromatin immunoprecipitation experiments have shown that Notch1 and NF-κB
subunits can be found on the Ifng promoter and this interaction could be abolished with
GSI treatment, suggesting that Notch1 and NF-κB work in tandem to promote IFNγ
expression (Shin et al., 2006). In addition, Notch1 and NF-κB could also be found in a
complex on the promoters of Eomes, Granzyme b and Perforin, and this interaction could
also be abrogated with GSI treatment (Cho et al., 2009).
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1.7.3 Cross talk between Notch and PKCθ pathways

Although the exact mechanism by which the Notch and PKCθ pathways interact
is unclear, their interaction seems inevitable in T cells because of the important role they
both play in the NF-κB pathway. For example, the formation of the CBM complex
requires both Notch and PKCθ, as described previously; however, data from our lab
suggests that these two proteins may interact with each other as well. Using microscopy
and biochemical approaches, our lab has shown that Notch and PKCθ co-localize at the
immunological synapse and physically interact as part of the CBM complex (Shin et al.,
2014). Additionally, earlier reports have shown synergistic activities between PKCθ and
NotchIC in T-ALL models induced by cells containing activating NotchIC mutations (Felli
et al., 2005; Giambra et al., 2012). Because it is unclear when and why during T cell
activation PKCθ and Notch interact, elucidation of these signaling pathways can shed
light on diseases in which these pathways are dysregulated. A summary of how these
pathways interact can be found in Figure 1.8.

1.8 MicroRNAs

1.8.1 Biogenesis and Modulation of Protein Expression

MicroRNAs (miRNAs) are a class of evolutionarily conserved, single-stranded,
non-coding RNAs that control protein expression at a post-transcriptional level. They
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have been detected in mammals, plants, and viruses, and have been described to affect
multiple signaling pathways in these systems (Bartel, 2004). To date, miRNAs have been
predicted to control the expression of 30% of genes in the mammalian genome, and
deregulation of microRNAs have been implicated in numerous human diseases including
many autoimmune diseases (Filipowicz et al., 2008).
MicroRNAs can be found in gene clusters (like miR-17-92 cluster) or in single
units scattered across the genome (like miR-155). MicroRNAs are mainly grouped in
what was previously thought of as “junk DNA” or the introns and intergenic portions of
the DNA. However, some miRNAs have been found to be encoded in gene exons that do
not encode for proteins (such as miR-155 encoded in the Bic gene). Once miRNAs are
encoded, primarily by RNA Polymerase II, primary transcripts that are about 80
nucleotides long are generated and folded into hairpin structures that have a 5’-cap and a
3’-polyA tail. The primary structures are then processed into approximately 70
nucleotides-long pre-miRNA stem loop structures in the nucleus by a nuclear
microprocessor that contains the RNase III enzyme, Drosha, and a double-stranded-RNAbinding protein DGCR8 (Digeorge syndrome critical region gene 8). The pre-miRNA
stem-loop structures are then transported to the cytoplasm through the exportin 5
complex (Denli et al., 2004).
Once in the cytoplasm, the pre-miRNA structures are then processed further by
the endonuclease, Dicer, along with its cofactors ,TAR RNA-binding protein (TRBP) and
PKR-activating protein (PACT), which cleave the pre-miRNA structure into 21–24 base
pair duplex miRNA, containing 2 nucleotides that overhang the 3′ of each strand
(Chendrimada et al., 2005). One strand is then loaded onto the RNA induced silencing
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complex (RISC) containing Argonaute (AGO) proteins (Diederichs and Haber, 2007).
Once the miRNA is loaded onto the RISC complex, miRNAs pair with their target
mRNA based on the complementarity of the microRNA seed sequences (nucleotides in
positions 2–8 from the 5ʹ end of an miRNA) to the 3’ UTR (untranslated region) of the
mRNA target. If there is perfect complementarity between the seed sequence and the 3’
UTR target sequence, the mRNA will be degraded. If there is imperfect complementarity,
there will be translational repression of the mRNA. The ability of miRNAs to bind with
different affinity to a multitude of different targets allows for a fine-tuning of gene
expression that can affect signaling. Figure 1.9 outlines the biogenesis of miRNAs.

1.8.2 MicroRNA-155 and the Immune System

MicroRNA-155 (miR-155) is a highly evolutionarily conserved microRNA that is
encoded in the second exon of the Bic (B-cell integration cluster) gene, which is
responsible for a subset of avian leukosis virus integration-induced lymphomas (Tam,
2001). It has been previously shown that miR-155 can transform B cells, resulting in
lymphoma in mouse models (Costinean et al., 2006). miR-155 is expressed in both
myeloid and lymphoid progenitors at different levels, depending on the cell type. During
erythrocyte maturation, miR-155 expression decreases (Masaki et al., 2007). Also,
transducing a K562 cell line with miR-155 significantly reduces their ability to
differentiate into erythroid or megakaryocyte lineages (Georgantas et al., 2007). miR-155
expression is increased in a human monocytic cell line when the cell line was stimulated
with LPS (Taganov et al., 2006). Also, addition of PolyI:PolyC (polyriboinosinic–
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polyribocytidylic acid) or TNF can induce miR-155 expression in macrophages through
JNK pathway activation (O'Connell et al., 2007).
The expression of miR-155 is necessary for B cell immunity. When BIC/miR-155
deficient mice were developed, they were found to have a severe defect in B cell IgM
production and switched antigen-specific antibodies when immunized with tetanus toxin
fragment C protein (Rodriguez et al., 2007). In a study utilizing a separate BIC/mir-155
deficient strain, miR-155 deficient mice had reduced germinal center function, cytokine
production, and T cell-dependent antibody response (Thai et al., 2007). In antigenstimulated B cells, miR-155 targets expression of PU.1 driving B cell maturation and IgG
class switching, and there is a highly conserved target sequence in the 3’ UTR region of
PU.1 (Vigorito et al., 2007). Also, miR-155 targets and represses expression of the
enzyme activation-induced cytidine deaminase, or AID (Dorsett et al., 2008; Teng et al.,
2008). AID is important for the process of somatic hypermutation that is required for
high-affinity IgG antibody repertoire in antigen-activated B cells by deaminating cytosine
residues and introduces U:G mismatches in DNA.

1.8.3 miR-155 and T cell function

miR-155 is important in many T cell signaling processes, from stimulation to
differentiation. Upon stimulation through the TCR, miR-155 expression is upregulated
(Dudda et al., 2013; Gracias et al., 2013; Thai et al., 2007). Most T cell lineages in miR155 deficient mice develop normally, however, CD4+ T cells differentially skew to Th2
in vivo with higher amounts of IL-4 produced under neutral stimulation conditions
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(Rodriguez et al., 2007; Thai et al., 2007). Since c-Maf has been shown to be a target of
miR-155, T cells deficient in miR-155 would have higher c-Maf production, and thus
have higher IL-4 production (Rodriguez et al., 2007). miR-155 is also important for CD8+
effector responses through the regulation of type 1 interferon signaling and through the
regulation of SOCS1 and STAT5 signaling (Dudda et al., 2013; Gracias et al., 2013).
miR-155 is also important in Tregs through its repression of SOCS1, and miR-155
deficient animals have reduced absolute numbers of Treg cells (Lu et al., 2009). miR-155
deficient T cells also have a defect in IL-17 production with less Th17 cells produced
(Murugaiyan et al., 2011; O'Connell et al., 2010; Yao et al., 2012). This defect in IL-17
production is due to the inability of miR-155 deficient cells to respond to IL-23 through
the transcription factor Ets1 (Hu et al., 2013).
Because of the important role that miR-155 plays in T cell stimulation and
differentiation, its dysregulation is evident in many autoimmune diseases. High levels of
miR-155 have been found in patients with multiple sclerosis, rheumatoid arthritis, and
atopic dermatitis (Junker et al., 2009; Sonkoly et al., 2010; Stanczyk et al., 2008).
Additionally, mice deficient in miR-155 do not develop EAE or collagen-induced
arthritis (Bluml et al., 2011; Hu et al., 2013; O'Connell et al., 2010; Yao et al., 2012).
Additionally, miR-155 deficient CD8+ cells were ineffective at controlling tumor growth
while overexpression of miR-155 enhances the anti-tumor response (Dudda et al., 2013).
miR-155 has also been shown to regulate T cell response to infectious pathogens, such as
the response to viruses (Lind and Ohashi, 2014).
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1.9 Programmed Death Receptor Signaling

1.9.1 The Programmed Death Signaling Pathway

The Programmed Death-1 (PD-1; CD279) receptor is an inhibitory receptor that is
found on the cell surface. It is made up of a single immunoglobulin (Ig) superfamily
domain and a cytoplasmic domain containing two tyrosine-based signaling motifs: a
tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch
motif (Ishida et al., 1992). PD-1 has two receptors: PD-L1 (B7-H1, CD274) and PD-L2
(B7-H2, CD273), and both ligands have Ig-V-like and Ig-C-like extracellular domains
and a short intracellular domain (Dong et al., 1999; Latchman et al., 2001; Tseng et al.,
2001).
PD-1 is expressed on natural killer T (NKT) cells, NK cells, activated monocytes,
some subsets of dendritic cells (DCs), and T and B cells. PD-1 is upregulated on T and B
cells after TCR or BCR stimulation, and sustained antigen stimulation sustains high PD-1
expression (Freeman et al., 2006). Cytokines such as IL-2 and interferons can also
potentiate PD-1 expression on T cells (Kinter et al., 2008). PD-L1 is broadly expressed
throughout cell subtypes, while PD-L2’s expression is more restricted. PD-L1 is
constitutively expressed on not only hematopoietic lineages, such as T and B cells, DCs,
macrophages, mesenchymal stem cells and bone marrow-derived mast cells, but it is also
expressed on many non-hematopoietic lineages (Freeman et al., 2000; Yamazaki et al.,
2002). These include vascular endothelial cells, epithelial cells, muscle cells,
hepatocytes, placental cells, pancreatic islet cells and stromal cells of the bone marrow
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(Eppihimer et al., 2002; Liang et al., 2003). Although PD-L1 is broadly expressed,
inflammatory molecules, such as IFNγ, can induce the upregulation of PD-L1 expression.
PD-L2, conversely, has a more limited expression on hematopoietic cell subtypes, such
as DCs, macrophages, bone marrow-derived mast cells and on peritoneal B1 B cells as
well as on germinal center B cells (Zhong et al., 2007). PD-L2 expression is not as
inducible as PD-L1 expression, but IL-4 and GM-CSF are the strongest known stimuli for
inducing PD-L2 expression (Eppihimer et al., 2002; Latchman et al., 2001; Loke and
Allison, 2003; Schreiner et al., 2004; Yamazaki et al., 2002).

1.9.2 PD-1/PD-L1 Signaling in T cell function

The major role of PD-1 signaling in T cells is the inhibition of T cell activation by
the engagement of the PD-1 receptor on the T cell by PD-L1 on the APCs. Certain
subsets express a high level of PD-1, such as CD4+Foxp3+ regulatory T cells and
“exhausted” CD8 cells (Baecher-Allan et al., 2003; Wherry et al., 2007). After ligation of
PD-1 in the presence of TCR signaling, the receptor transduces an inhibitory signal
through phosphorylation of the tyrosine residue on the ITSM region of its cytoplasmic
tail. This leads to the recruitment of SHP-2 (SH2-domain containing tyrosine phosphatase
2) and possibly SHP-2, to the cytoplasmic domain of PD-1. This then downregulates
PI3K activity mediated by CD28, thus downregulating the activation of Akt and T cell
activation as shown in Figure 1.10 (Parry et al., 2005). PD-1 ligation has also been shown
to inhibit phosphorylation of CD3, ZAP70 and PKCs, thus inhibiting signaling directly
downstream of the TCR (Parry et al., 2005). PD-L1 can also inhibit T cell stimulation
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when expressed on T cells by binding the CD80 molecule (B7-1) and blocking the
engagement of CD28 with CD80, thus inhibiting proper T cell stimulation (Butte et al.,
2007).
Other than affecting T cell activation downstream of the TCR, PD-1 activation
also effects downstream effector signaling pathways, either during migration to the site of
inflammation, or in the target tissue (Keir et al., 2008; Riella et al., 2011). PD-1
activation dramatically decreases the production of IL-2, IFNγ, and TNF, thus affecting T
cell proliferation (Keir et al., 2008; Latchman et al., 2001). PD-1 activation also
decreases the expression of the effector T cell associated transcription factors, GATA-3,
T-BET, and Eomes (Nurieva et al., 2006). Additionally, PD-1 signaling has been shown
to promote iTreg development, and PD-L1 engagement of its receptors on naïve T cells
promotes iTreg development by inhibiting mTOR/Akt signaling (Francisco et al., 2009).
Amarnath and colleagues have also shown that PD-L1:PD-1 signaling can be used in a
human-into-mouse GVHD model to convert human Th1 cells into iTregs in vivo
(Amarnath et al., 2011). It is clear from this evidence that PD-L1:PD-1 signaling is
important in the maintenance of proper T cell function and the protection against aberrant
T cell signaling.

1.9.3 The PD-1/PD-L1 Signaling and Disease Regulation

Because of the important role of PD-1 signaling in T cells, its dysregulation has
been linked to many autoimmune diseases. Mice that are deficient in PD-1 develop
autoimmune disease over time because of the loss in peripheral tolerance. The type of
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autoimmune disease they develop depends on the strain of mouse. For example, mice
deficient for PD-1 develop a lupus-like glomerulonephritis and arthritis on a C57BL/6
background, while they develop dilated cardiomyopathy on a BALB/C background
(Nishimura et al., 2001). PD-L1 expression on parenchymal cells have also been shown
to protect against autoimmune diabetes (Keir et al., 2006). Single-nucleotide
polymorphisms in the gene PDCD1 (gene encoding for PD-1), has been found in various
kinds of autoimmune diseases, including SLE, type I diabetes, multiple sclerosis,
rheumatoid arthritis, Grave’s disease, ankylosing spondylitis, and aplastic anemia (James
et al., 2005; Nielsen et al., 2003; Prokunina et al., 2002; Wu et al., 2013). Although
dysregulation of PD-1 signaling is evident in many autoimmune diseases, no agonist for
PD-1 or its ligands is currently in clinical trials.
In normal immune function, PD-1 is responsible for attenuating the primary
immune response during acute infection. Using a model of adenovirus-induced hepatitis,
PD-1 deficiency causes a significant decrease in the proliferation and accumulation of
effector T cells in the liver. This also causes a rapid clearance of the virus; however,
mice deficient in PD-1 conversely develop severe hepatitis, probably since PD-1 is
responsible for dampening the cytokine storm that leads to excess tissue damage (Iwai et
al., 2003). After chronic viral infection (such as with LCMV clone 13), viral specific PD1hiCD8+ T cells become anergic and unresponsive, or “exhausted.” They lose their
ability to produce TNF, IFN-γ, and IL-2. Although this population is not functionally
competent, they contain memory cells that can re-expand after secondary infection with
acute forms of the virus (Barber et al., 2006).

	
  

37	
  

	
  
Clinically, PD-1:PD-L1 signaling has been mostly scrutinized in cancer models.
The PD-1:PD-L1 pathway plays a major role in dampening the immune surveillance
against tumors. Overexpression of PD-L1 on plasmacytoma cell inhibits cytolytic activity
of CD8+ T cells through engagement of PD-1, and enhances the growth and invasiveness
of the plasmacytoma (Iwai et al., 2002). Additionally, high expression of PD-L1 on
clinical samples of tumors is associated with poor prognosis (Thompson et al., 2004).
Also, blocking PD-1:PD-L1 interaction through antibody inhibition or genetic
manipulation has been shown to accelerate the eradication of tumors in various
experimental models (Blank et al., 2004; Curiel et al., 2003; Hirano et al., 2005; Strome
et al., 2003). Currently, there is a fully humanized mAB to PD-1 (also known as
nivolumab) that has made it through phase I clinical trials with little toxicity, as well as a
mAb to PD-L1 (BMS-936559 or MDX-1105) that has also made it through some clinical
trials, both with a potential for strong antitumor activity (Brahmer et al., 2010; Brahmer
et al., 2012; Topalian et al., 2012). Although its efficacy in cancer treatment may prove
high, it has not yet been determined the effect that blocking PD-1 signaling may have on
worsening GVHD after bone marrow transplantation, which is a treatment used for some
cancers.

1.10 Significance and Hypothesis

Although most patients respond to standard therapy (BMT or IST) given to
Aplastic Anemia patients, there is still a large cohort of patients who do not respond to
this therapy and succumb to disease. Because no autoantigen to this disease has been
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found, elucidating the mechanisms driving the pathogenic T cell response is paramount to
developing other treatments for patients who are refractory to treatment or relapse.
Therefore, through the following specific aims, we intend to extend the understanding of
pathogenic T cell signaling pathways driving Aplastic Anemia:

Specific Aim I: Determine if PKCθ works in conjunction with Notch1 signaling to drive
AA pathogenesis.
Specific Aim II: Elucidate the role NF-κB plays in the disease pathology of Aplastic
Anemia.
Specific Aim III: Determine if miR-155 drives disease severity of AA, and understand
the mechanism of its signaling.

Using our murine model of AA and patient samples, we sought to evaluate these
aims to find pathways that could prove to be novel targets for therapy. We hypothesize
that PKCθ works in conjunction with Notch signaling to drive AA both in the mouse
model and patient samples. Also, we predict that targeting NF-κB using small molecule
inhibitors can ameliorate disease symptoms through the down regulation of CXCR4
expression and suppression of T cell activation. Also, we hypothesize that miR-155
expression is increased in mice with AA compared to controls, and genetically deleting
miR-155 in our mouse model mitigates disease severity through an increase in PD-L1
expression on T cells. The findings of this work can not only be used to further clinical
translational research for Aplastic Anemia, but also for any autoreactive T cell signaling
driving autoimmune diseases
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Figure 1.1 T Cell Receptor Signaling
Signals delivered by the engagement of the T-cell receptor and co-stimulatory molecules
induce different signaling pathways that result in the activation of multiple transcription
factors. Ligation of the TCR by peptide–MHC complexes triggers the recruitment of
signaling molecules, such as Zap70, LAT, and SLP76. Downstream signaling activates
the NF-κB pathway, NFAT pathway, and AP-1 pathway to promote a program of gene
expression that leads to interleukin-2 (IL-2) production and T cell activation. Adapted
from Miller et al., 2007.
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Figure 1.2 T Cell Subsets
A. Following activation by APCs, naive CD4+ T cells can be polarized into different
effector T cell subsets depending on the local cytokine environment. The differentiation
of each of these effector T cell subsets is controlled by distinct sets of transcription
factors. Adapted from Zou and Restifo, 2010. B. After activation of naïve CD8+ by
APCs, CD4+ T cells or MHCI presentation, CD8+ effector cells produce chemokines,
cytokines and apoptotic proteins in order to eliminate infected cells. Adapted from De
Haes, et al., 2012.
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Figure 1.3 Immunopathogenesis of the bone marrow in Aplastic Anemia
Unknown self-antigens are presented to T lymphocytes by antigen presenting cells
(APCs), which trigger T cells to activate and proliferate. Increased production of IL-2
leads to polyclonal expansion of T cells, and the upregulation of T-bet causes
differentiation of T cells to a Th1 program. IFNγ and TNF upregulate other T cells'
cellular receptors and also the Fas receptor. The expression of these proteins activate
apoptosis programs in hematopoietic stem cells resident in the bone marrow, and leads to
the pancytopenia that is associated with AA. Adapted from Young, 2006.
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Pfeifhofer-Obermair et al.

Flavor of PKC in T cell

A
A

FIGURE 1 | The human PKC gene family. PKC proteins are classified into
conventional PKCs (cPKC; α, β, and γ), novel PKCs (nPKC; ε, δ, θ, and η) and
atypical PKCs (aPKC; ζ and ι). cPKCs require Ca2+ and diacylglycerol (DAG)
for activation, nPKCs are Ca2+ independent and aPKCs require neither
Ca2+ nor DAG for activation.

B
antigen 1), and CD45 (Freiberg et al., 2002). Effective T cell stimulation is characterized by the recruitment of PKCθ to the SMAC
(Schaefer et al., 2004), at which it is phosphorylated by LCK at
Tyr-90 (Liu et al., 2000). A physical interaction of PKCθ with the
cytoplasmatic tail of CD28 has been shown to be essential in this
recruitment mechanism (Kong et al., 2011). Subsequently, PKCθ is
phosphorylated at different sites (Bauer et al., 2001; Bi et al., 2001;
Liu et al., 2002; Freeley et al., 2005; Lee et al., 2005) and autophosphorylated at Thr-219 (Thuille et al., 2005). Recently, Chuang et al.
(2011) identified the MAP4K3 GCK-like kinase (GLK) as a kinase
that directly phosphorylates PKCθ at Thr-538 which is essential
to activation of NF-κB in T cells. Phosphorylation is important
to retain PKCθ in the immunological synapse, in which one of its
functions seems to be the regulation of the immunological synapse
itself. Through the live imaging of components of the immunological synapse, the synapse has been shown to be dynamic
in wild-type mice but more stable in PKCθ-knockout mice,
which influences the strength, duration and location of signals
(Dustin, 2008).
RECRUITMENT AND ACTIVATION OF SIGNALING MOLECULES

Another important role of PKCθ is to recruit and activate signaling molecules, such as phospholipase C (PLC), IL2-inducible
T cell kinase (ITK), TEC, phospholipase C γ 1 (PLCγ1), and SPAK
(a MAPKKK that ultimately activates AP1) to the immunological synapse. PKCθ was identified to play a critical role in the
NF-κB and Ca2+ /NFAT pathways to activate the IL-2 promoter.
Antigen binding to the TCR leads to an increase in intracellular Ca2+ , which activates calcineurin. Calcineurin dephosphorylates NFAT and leads to its nuclear import. Subsequently,
NFAT forms complexes with the AP-1 protein transcription factor family and regulates the expression of IL-2 by binding to
its promoter. PKCθ-knockout T cells were first described by

Figure 1.4 PKC Family Members

FIGURE 2 | Involvement of individual PKC family members in different
aspects of T cell biology. Numerous studies identified PKC
isotype-selective functions in signaling pathways, necessary for full T cell
activation, differentiation and robust immune responses in vivo (for details
see text). The dashed line depicts PKC functions which were characterized
primarily via overexpression/knockdown studies in immortalized cell lines,
while a validation in a more physiological system is pending.

Sun et al. (2000). They generated PKCθ-knockout mice by replac
ing the exon encoding the ATP-binding site of the kinase domain
with the neomycin resistance gene. In their study they found
strongly reduced proliferation of PKCθ−/− CD3+ T lympho
cytes accompanied by a reduced secretion of IL-2. Suitably they
could show that TCR-initiated NF-κB activation was absent from
PKCθ−/− CD3+ T lymphocytes but was normal in thymo
cytes indicating that PKCθ is essential for TCR-mediated T cel
activation (Sun et al., 2000).
Pfeifhofer et al. (2003) generated a conditional PKCθ-knockou
mouse by using Cre-mediated recombination where the complet
coding sequences of exons 3 and 4 are deleted, followed by
frame shift mutation between exons 2 and 5. Additionally to th
results Sun et al. (2000) observed, they saw that a deficiency o
PKCθ abrogates NFAT transactivation after CD3/CD28 stimula
tion. In addition, decreased intracellular Ca2+ flux was observed
(Pfeifhofer et al., 2003).
To induce and maintain the complete IL-2-producing capac
ity of a T cell after TCR stimulation and activation of CD28, th
RING (really interesting new gene)-type E3 ubiquitin ligase Cbl-b
must be inhibited. Cbl-b restricts activation of the TCR by inhibit
ing the activation of PI3K (phosphoinositide-3-kinase; Fang and
Liu, 2001) and PLCγ1 (Heissmeyer et al., 2004; Jeon et al., 2004)
and it promotes the antigen-induced downregulation of the TCR
(Naramura et al., 2002). In response to the stimulation of CD28
Cbl-b is ubiquitinylated and proteasomally degraded. Gruber et al
(2009a) showed that PKCθ directly regulates the ubiquitinylation
and degradation of Cbl-b. After co-stimulation of the TCR and
CD28, Cbl-b was degraded in wild-type CD3+ T cells but no
PKCθ-deficient CD3+ T cells, and the ubiquitinylation of Cbl-b
was strongly decreased after treatment with an inhibitor of PKCθ
(Gruber et al., 2009a).

A. Structure of PKC proteins. PKC proteins are classified into conventional PKCs
(cPKC; α, β, and γ), novel PKCs (nPKC; ε, δ, θ, and η) and atypical PKCs (aPKC; ζ and
ι). All families have the kinase region and C1 region (Constant 1 region), while only
cPKCs have a Ca2+ binding region. Adapted from Pfeifhofer-Obermair et al., 2012. B.
Activation of PKCθ. Ligation of the TCR induces the activation of tyrosine kinase LCK,
ZAP-70, induces phosphorylation of SLP-76. SLP-76 directly interacts with and activates
PLCγ1 which cleaves a phospholipid, generating the second messenger DAG. The
Frontiers in induces
Immunology | a
T Cell
Biology
binding of DAG with PKC-θ
conformational
change; T538 of PKC-θ is thenAugust 2012 | Volume 3 | Article 220 |
phosphorylated by GLK, leading to catalytic activation of PKC-θ. The CD28
costimulatory activates PDK-1, which facilitates PKC-θ T538 phosphorylation. Catalytic
“fimmu-03-00220” — 2012/8/2 — 17:12 — page 2 — #2
activation and membrane translocation of PKC-θ lead to the activation of transcription
factors NF-κB, NF-AT, and AP-1, and to subsequent T cell activation. Adapted from
Wang et al., 2012.
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Figure 1.5 Notch Signaling Pathway
A. Structural representation of Notch receptors and their ligands. All receptors contain an
extracellular domain with EGF-like repeats, the LIN domain for heterodimerization,
RAM domain and ankyrin repeats for binding proteins and PEST domain for protein
degradation. Notch3 and Notch4 lack a transcriptional activation domain (TAD). All
ligands contain EGF-like repeats and a conserved DSL sequence. Jagged ligands have an
additional cysteine rich (CR) domain. B. Canonical Notch Signaling. After fucosylation
in the ER, Notch transits into the Golgi where it is cleaved at the S1 site by a furin-like
protease. This leads to the expression of a non-covalently linked hetero-dimeric receptor
on the cell surface. Following ligand binding, a second cleavage at the S2 site by an
ADAM protease leads to the shedding of the extracellular domain. Following
ubiquitination, the rest of the receptor is endocytosed and cleaved at the S3 site by a γsecretase. This releases the intracellular, active domain of Notch, which migrates into the
nucleus and interacts with CSL/RBP-Jκ, previously associated with co-repressors (CoR).
Recruitment of co-activators (CoA) converts CSL to an activator of transcription leading
to transcription of target genes. Adapted from Osborne and Minter, 2007.
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Figure 1.6 NF-κB Signaling Pathway
A. Structure of NF-κB subunits. All subunits share an approximately 300 amino acidlong DNA binding and dimerization domain that is termed the REL homology domain
(RHD). RelA, RelB and c-Rel all contain carboxy-terminal transactivation domains
(TADs), and RelB has an amino-terminal leucine zipper (LZ)-like motif. p52 and p50 are
derived from proteolysis of their precursor proteins p100 and p105, respectively (not
shown). Adapted from Perkins, 2012. B. TCR signaling pathway used in mature T cells
to activate NF-κB. Antigen-MHC and CD80 or CD86 binding to the TCR and CD28,
respectively, engage and activate kinase signaling cascades (Fyn-PI(3)K, PDK1 and
PKCθ) that through the recruitment of a specific signaling adaptor network involving the
CMB complex, TRAF (TRAF2 and TRAF6) and TAB (TAB1 and TAB2) proteins,
activates the canonical NF-κB pathway via the TAK1-dependent phosphorylation of
IKKβ. Adapted from Gerondakis et al., 2014.
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Figure 1.7 CXCR4 Signaling Pathway
CXCR4 signaling in T cells. When CXCR4 binds to CXCL12 (or SDF-1), it induces a
conformational change of CXCR4/G-proteins and triggers GPCR signaling through
PI3K/Akt, PLC/IP3, and ERK1/2 pathways, thus regulating cell survival, proliferation,
and chemotaxis. Beta-arrestin pathway can be activated through GRK to internalize
CXCR4. Adapted from Wurth et al., 2014.

	
  

46	
  

	
  

!"#$%

Figure 1.8 Signaling Pathway Cross Talk in T cells
An overview on potential steps downstream of TCR signaling where the Notch, NF-κB,
and PKCθ pathways are interacting. Adapted from Gerondakis et al., 2014 and Osborne
and Minter, 2007.
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Figure 1. miRNA biogenesis and action in animal cells

Mature miRNAs are short (with average about 22 nts long), single stranded RNA molecules
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Figure 1.10 PD-1/PD-L1 Signaling Axis
A. PD-1 signaling in T cells. PD-1 signaling dephosphorylates proximal signaling
molecules and augments PTEN expression, inhibiting PI3K and AKT activation. The
consequences include decreased T cell proliferation, cytokine production and cell
survival. Adapted from Riella et al., 2012. B. B7-1:PD-L1 interaction expands pathways
in the B7:CD28 family. PD-L1 and B7-1 productively interact on T cells and can deliver
bidirectional inhibitory signals. PD-L1:B7-1 binding may not only deliver signals when
ligated, but may also serve to segregate binding away from previously identified
receptors (PD-1, CD28, CTLA-4). IgV-like regions are depicted in blue and IgC-like
regions in green, while tyrosine-containing signaling motifs are depicted by Ys. Adapted
from Keir et al, 2008.
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CHAPTER 2

PKCθ ACTS UPSTREAM OF NOTCH1 TO CONTRIBUTE TO THE
PATHOGENESIS ASSOCIATED WITH APLASTIC ANEMIA

2.1 Introduction

Severe aplastic anemia (AA) is a rare acquired bone marrow failure (BMF)
syndrome. At the time of diagnosis, patients often present with low levels of circulating
platelets, white and red cells, and a characteristic hypocellular bone marrow (Young et
al., 2008). Immune-mediated destruction of hematopoietic stem and progenitor cells,
together with compromised stromal cell integrity in the bone marrow, leads to peripheral
pancytopenia and leaves patients susceptible to bleeding episodes, infection, and hypoxia
(Chen et al., 2005; Young et al., 2008). Most cases of AA are of unknown etiology and, if
left untreated, can be fatal (Dezern and Brodsky, 2011).
The clinical observation that the majority of AA patients respond to
immunosuppressive therapy underscores an autoimmune mechanism driving disease
progression (Young et al., 2006). Evidence points to autoreactive T helper type-1 (Th1)
lymphocytes as instrumental in mediating disease. Circulating T cells from patients with
AA express increased levels of the Th1 transcriptional regulator, T-BET (Solomou et al.,
2006), as well as intracellular NOTCH1, which directly regulates T-BET expression
(Roderick et al., 2013). In the diseased bone marrow, elevated levels of proinflammatory,
Th1-associated cytokines, IFNγ and TNF, suppress hematopoiesis and damage stromal
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cells lining the hematopoietic niches through by-stander effects (Chen et al., 2004;
Giannakoulas et al., 2004; Sloand et al., 2002; Young, 1987; Young et al., 1987;
Zoumbos et al., 1985). Approximately 30% of newly-diagnosed patients do not respond
to a single round of immunosuppressive therapy. Thus, new studies aimed at elucidating
the cellular mechanisms at work in AA are critically important to identify novel
therapeutic targets.
Full T cell activation is a sequential process. It is initiated when the T cell
receptor (TCR) binds antigen displayed on an antigen presenting cell; a second signal is
delivered when the T cell co-receptor, CD28, engages its cognate ligand, also found on
the APC. Subsequently, cytokines generated in response to antigenic stimulation further
act on T cells to drive their proliferation and differentiation. Protein kinase C-theta
(PKCθ) is a novel member of the PKC family of kinases. Its activity, which is central to
T cell signaling, is Ca2+-independent (Ono et al., 1988). Following T cell stimulation,
PKCθ is activated through phosphorylation by germinal center kinase (GSK)-like kinase
(GLK; Chuang et al., 2011), a process that can be successfully inhibited
pharmacologically, using the PKCθ inhibitor, rottlerin (Springael et al., 2007). Physical
redistribution of phosphorylated PKCθ within the fluid domains of the cell membrane
results in its accumulation at the APC-T cell interface, where it facilitates assembly of a
macromolecular signaling aggregate, known as the CARMA1-BCL10-MALT1 (CBM)
complex (Sommer et al., 2005; Sun et al., 2000). CBM assembly is an integral step in the
signaling process that links TCR engagement to gene transcription critical for T cell
survival, proliferation, and differentiation (Matsumoto et al., 2005; Wang et al., 2004).
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Together with PKCθ, the transmembrane receptor, NOTCH1, has been shown to
be indispensable for assembly of the CBM complex, suggesting PKCθ and NOTCH1
function within intersecting signaling pathways (Shin et al., 2014). In mammals, the
NOTCH family comprises four cell surface receptors (NOTCH1-4) that are critical
regulators of cell fate acquisition in multiple cell types, including T cells during
thymocyte development (Deftos and Bevan, 2000; Osborne and Minter, 2007). In mature
T cells NOTCH1 mediates survival, proliferation, differentiation, and cytokine
production in response to antigenic stimulus (Adler et al., 2003; Osborne and Minter,
2007; Palaga et al., 2003; Zhang et al., 2011). A role for aberrant NOTCH signaling in
autoimmune disease, including AA, is also emerging (reviewed in Palaga and Minter,
2013; Roderick et al., 2013).
How PKCθ may contribute to T helper cell-mediated processes remains
controversial. Reports suggest PKCθ is required for Th2 and Th17 responses, but it has
been shown to be dispensable for generating Th1-mediated antiviral, as well as memory,
T cell responses (Kwon et al., 2012; Marsland et al., 2005; Marsland et al., 2004).
Accumulating evidence supports a function for PKCθ in mediating autoimmune
disorders, such as experimental autoimmune encephalomyelitis, rheumatoid arthritis, and
myosin-induced autoimmune myocarditis (Healy et al., 2006; Marsland et al., 2007;
Salek-Ardakani et al., 2005; Tan et al., 2006). Furthermore, in a mouse model of graftversus-host disease (GVHD), which has a strong Th1 component, PKCθ was required to
induce GVHD pathology, but not to clear viral pathogen or residual leukemic cells
(Valenzuela et al., 2009). These data suggest that inhibiting PKCθ in T cells may
abrogate their pathogenic activity, while preserving their ability to respond appropriately

	
  

52	
  

	
  
to infectious stimuli. Our lab has previously shown that PKCθ is necessary for the
development of AA in a mouse model of disease (Roderick, unpublished). Also,
theraputically treating mice induced with AA with rottlerin ameliorates disease symptoms
(Roderick, unpublished). As such, PKCθ may represent an attractive target for
modulating immune-mediated conditions.
We tested the hypothesis that PKCθ is critical driver of AA pathogenesis. Using
an established mouse model of AA shown in (Roderick et al., 2013), we demonstrate that
phosphorylated PKCθ (pPKCθ) is elevated in spleen- and bone marrow-infiltrating T
cells of AA mice, but not of control animals. Mechanistically, we show interfering
temporally with PKCθ signaling differentially affects the expression of the intracellular
domain of NOTCH1 (NOTCH1IC) in murine CD4+ and CD8+ T cells. Abrogating PKCθ
activity, pharmacologically or genetically, reduced NOTCH1IC and IFNγ expression.
Finally, we highlight the clinical relevance of our findings by demonstrating increased
levels of phosphorylated PKCθ in peripheral blood samples from AA patients, which we
show respond to in vitro rottlerin treatment by down-regulating NOTCH1IC expression
and IFNγ production. Collectively, our findings reveal PKCθ is an important contributor
to AA pathogenesis through its regulation of the NOTCH1 signaling axis.
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2.2 Results

2.2.1 Mice with aplastic anemia express high levels of pPKCθ in T cells

Phosphorylated PKCθ (pPKCθ) is required for full T cell activation (Liu et al.,
2002). As we began our investigation of how PKCθ might contribute to bone marrow
failure, our progress was hampered by the fact that the small number of cells recovered
from the bone marrow of AA mice, or even from patients’ peripheral blood, limits the use
of immunoblotting as a means of evaluating protein expression. Therefore, we used
conventional immunoblotting methods to validate a flow cytometric approach for
determining levels of pPKCθ (Figure 2.1, A and B), then examined the expression of
pPKCθ in T cells that mediate disease in a mouse model of AA (Roderick et al., 2013).
Using flow cytometry, we assessed pPKCθ expression in CD4+ and CD8+ T cells both in
the bone marrow and spleens of AA mice. Compared to control mice, which only receive
γ−irradiation, there is significantly more pPKCθ expression in CD4+ and CD8+ cells in
the bone marrow of AA mice on day 17 of the disease course (Figure 2.1, C and D). This
observation extended to the spleens of diseased mice whose CD4+ and CD8+ T cells also
showed increased pPKCθ, compared to T cells from γirradiated control mice (Figure 2.1,
E and F). These data indicate that T cells infiltrating the bone marrow and spleens of AA
mice express high levels of pPKCθ expression at the peak of disease.
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2.2.2 PKCθ acts upstream of and is necessary for NOTCH1IC and IFNγ expression
in stimulated T cells

Individually, NOTCH1 and PKCθ have been shown to be essential for successful
activation of T cells after stimulation through the TCR and the CD28 co-receptor (Adler
et al., 2003; Eagar et al., 2004; Helbig et al., 2012; Palaga et al., 2003; Sun et al., 2000).
Earlier studies showed treating peripheral blood mononuclear cells (PBMCs) from AA
patients, in vitro, with the PKCθ inhibitor, rottlerin, decreased T-BET expression, a
critical Th1 transcription factor frequently overexpressed in patients with AA (Solomou
et al., 2006). We showed previously that intracellular NOTCH1 (NOTCH1IC) is increased
in PBMCs from AA patients, and can be detected bound to the promoter of TBX21,
which encodes T-BET (Roderick et al., 2013). We therefore asked whether PKCθ might
function upstream of NOTCH1 during T cell activation. We stimulated WT murine T
cells in the absence or presence of rottlerin, or we stimulated PKCθ-/- T cells alone, and
assessed levels of intracellular NOTCH1IC using flow cytometry (Roderick et al., 2013).
T cells stimulated in the presence of rottlerin showed significantly reduced median
fluorescence intensity (MFI) of NOTCH1IC, both in CD4+ (Figure 2.2A) and CD8+ T
cells (Figure 2.2C). We noted similar decreases in NOTCH1IC when T cells isolated
from PKCθ-/- mice were stimulated under similar conditions (Figure 2.2, B and D).
In the earlier study, treating AA patient samples with rottlerin in vitro also
reduced their capacity to produce IFNγ (Solomou et al., 2006). Since NOTCH1 has been
shown to directly regulate IFNγ expression in murine T cells (Shin et al., 2006), we used
IFNγ as a biological readout to ask whether inhibiting PKCθ affects NOTCH1-mediated
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IFNγ secretion. Compared to DMSO-treated cells, abrogating PKCθ activity with
rottlerin significantly reduced IFNγ in CD4+ (Figure 2.2E) and CD8+ T cells (Figure
2.2G), as measured by intracellular cytokine staining. We also observed low levels of
IFNγ in stimulated PKCθ-/- CD4+ and PKCθ-/-CD8+ T cells (Figure 2.2, F and H).
Altogether, these results provide evidence that PKCθ acts upstream of NOTCH1 to
positively modulate its expression, as well as the production of the NOTCH1-regulated,
pro-inflammatory cytokine, IFNγ.

2.2.3 Differential requirements of PKCθ for NOTCH1IC expression in stimulated
CD4+ and CD8+ T cells

We recently demonstrated a physical interaction between PKCθ and NOTCH1
that occurs within 3 hours of T cell activation (Shin et al., 2014). In the present study, we
sought to better understand the extended temporal requirements of PKCθ activity on
NOTCH1IC expression. Specifically, we wanted to know whether inhibiting
PKCθ expression when T cells are activated affects NOTCH1IC expression. If so, are
these effects long-lived and, importantly, for therapeutic considerations, what are the
effects on NOTCH1IC expression when we perturb PKCθ signaling well beyond T cell
activation? To answer these questions, we isolated WT T cells and cultured them with
plate-bound anti-CD3ε and anti-CD28 under one of the following conditions: i) with
rottlerin added to culture medium at time of plating, ii) with rottlerin added at the time of
plating, but removed from cells when fresh medium was added 24 hours later, or iii) with
rottlerin added 24 hours after T cells were seeded into antibody-coated wells. DMSO was
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added to control wells under identical conditions as a vehicle control. We harvested cells
at 24-hour time points over a 96-hour culture period and utilized flow cytometry to assess
NOTCH1IC expression and intracellular IFNγ in CD4+ and CD8+ T cells. When rottlerin
was added at the time of T cell stimulation, NOTCH1IC expression both in CD4+ (Figure
2.3A left panel) and CD8+ T cells (Figure 2.3B, left panel) was significantly lower,
compared to DMSO-treated cells. We observed similarly-low levels of IFNγ in
stimulated CD4+ (Figure 2.3C, left panel) and CD8+ cells (Figure 2.3D, left panel) treated
with rottlerin, compared to those cultured with DMSO. These data suggest PKCθ
signaling at the time of T cell activation positively modulates NOTCH1IC expression as
well as IFNγ production.
We next asked whether inhibiting PKCθ signaling at the time of T cell stimulation
had durable effects on NOTCH1IC signaling. We found that even after removing
rottlerin-containing medium and replacing it with fresh medium 24 hours later, CD4+
(Figure 2.3A, center panel) and CD8+ T cells (Figure 2.3B, center panel) exposed to
rottlerin during stimulation exhibited significantly less NOTCH1IC compared to DMSO
treated controls. CD4+ (Figure 2.3C, center panel) and CD8+ T cells (Figure 2.3D center
panel) cultured under these conditions also produced less IFNγ. These results indicate
blocking PKCθ signaling, even for relatively short durations at the time T cells are
stimulated, has long-lasting effects on NOTCH1IC expression and its downstream targets,
including IFNγ.
Finally, we assessed the extent to which blocking PKCθ signaling as late as 24
hours after T cell activation affects NOTCH1IC expression and IFNγ production. To our
surprise, when T cells were stimulated for 24 hours before rottlerin was added to cultures,
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we observed a significant decrease in NOTCH1IC in CD8+ (Figure 2.3B, right panel) but
not in CD4+ T cells (Figure 2.3A, right panel). Consistent with its effects on NOTCH1IC
expression, blocking PKCθ 24 hours after T cell activation also inhibited IFNγ
production in CD8+ (Figure 2.3D, right panel) but not in CD4+ T cells (Figure 2.3C, right
panel). Altogether, these data reveal CD4+ and CD8+ T cells exhibit a differential
requirement for PKCθ signaling during NOTCH1IC induction and IFNγ production. We
conclude that CD8+ T cells require uninterrupted PKCθ signaling to maintain NOTCH1IC
expression. It would seem CD4+ T cells do not have this same degree of stringency, since
they are able to maintain NOTCH1IC expression as long as PKCθ is present at the time of
activation. These data have important clinical ramifications, since they support the notion
that interrupting PKCθ signaling in activated CD8+ T cells may further disrupt
NOTCH1IC expression and IFNγ production, to potentially attenuate disease symptoms.

2.2.4 Peripheral T cells from patients with AA express high levels of pPKCθ which
respond to rottlerin treatment by downregulating NOTCH1IC and IFNγ

PBMCs from patients with AA express elevated levels of Th1-associated proteins,
including T-BET and Rottlerin treatment decreased T-BET expression and IFNγ
secretion (Solomou et al., 2006). Moreover, we previously noted increased expression of
NOTCH1IC in peripheral T cells from AA patients, and demonstrated that it was enriched
at the promoter that regulates T-BET (Roderick et al., 2013). Intrigued by these
overlapping findings, we asked whether Rottlerin treatment also affected NOTCH1IC
expression in AA patient samples. We used flow cytometry to evaluate the level of

	
  

58	
  

	
  
active, phosphorylated PKCθ (pPKCθ) in unmanipulated PBMCs from a cohort of AA
patients who had not received prior treatment. Compared to healthy controls, the PBMCs
of patients with untreated AA expressed significantly higher levels of pPKCθ both in
CD4+ and CD8+ T cells (Figure 2.4, A and B). We investigated whether these cells would
respond to PKCθ inhibition by down-regulating NOTCH1IC expression, as we had
observed with murine T cells. We seeded PBMCs from healthy donors, or from patients
with untreated AA, into tissue culture wells pre-coated with antibodies specific for CD3ε
and CD28, and cultured cells for 72 hours in the presence of rottlerin or DMSO, as
vehicle control. We determined that both in CD4+ and CD8+ T cells of AA patients,
NOTCH1IC levels were significantly lower after rottlerin treatment, compared to those
treated with DMSO (Figure 2.4, C and D). This reduced NOTCH1IC expression could
also be seen in healthy PBMC controls suggesting that, although AA patient samples
express significantly higher levels of pPKCθ, the PKCθ expressed responds equivalently
to the actions of rottlerin.
As a biological readout of NOTCH1IC activity, we quantified IFNγ production by
stimulating PBMCs from healthy controls or from patients with AA, treated with DMSO
or rottlerin. PBMCs from both cohorts responded to rottlerin treatment by secreting
significantly less IFNγ into culture supernatants (Figure 2.4E), compared to DMSOtreated controls, indicating Rottlerin can effectively reduce the expression of key
inflammatory proteins associated with AA pathology. Consistent with the increased
expression of pPKCθ we noted in AA mice, we noted pPKCθ is also expressed at high
levels in patients with AA who have not received prior IST. Furthermore, PBMCs from
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patients are not refractory to Rottlerin treatment but rather respond by down regulating
both NOTCH1IC expression and IFNγ secretion.

2.3 Discussion

Phosphorylated PKCθ is elevated in T cells from mice and patients with AA.
Furthermore, we identify a specific requirement for PKCθ in CD8+ T cells, but not in
CD4+ T cells to drive IFN-γ. High levels of pPKCθ observed in human patient samples
responded to rottlerin treatment by reducing levels of NOTCH1IC expression and IFNγ,
two pro-inflammatory proteins that are frequently expressed in patients with AA
(Roderick et al., 2013, Solomou et al, 2006).
Our results firmly place PKCθ upstream of NOTCH1IC accumulation, following T
cell stimulation. Cross-talk between the NOTCH and PKC families has been reported in
multiple systems. Signaling pathways mediated by PKCα and NOTCH4 converge in
some instances of endocrine resistant breast cancer (Yun et al., 2013). Earlier reports
have shown synergistic activities between PKCθ and NOTCHIC in T cell acute
lymphoblastic leukemia models induced by cells containing activating NOTCHIC
mutations (Felli et al., 2005; Giambra et al., 2012). However, how PKCθ functions to
modulate NOTCH1 activation in normal, mature T cells remains ill-defined. In this study,
inhibiting PKCθ signaling at the time of TCR stimulation revealed a previously
undescribed requirement for this PKC family member, acting upstream of NOTCH1IC
and modulating its expression.
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These results extend and inform previous observations by Solomou et al. In that
report, treating PBMCs from AA patients with the PKCθ inhibitor, rottlerin, reduced
levels of the Th1 transcriptional regulator, T-BET, as well as the pro-inflammatory
cytokine, IFNγ. However, pPKCθ levels were not measured directly in that study, so it
remained unclear whether and how PKCθ might be acting to modulate T-BET and IFNγ
expression. In our present study, we directly measure pPKCθ, and show it is robustly
expressed in PBMCs from patients with AA. In agreement with Solomou’s observations,
patient PBMCs responded to Rottlerin treatment by downregulating IFNγ production. We
further demonstrate here, an as yet unreported effect of rottlerin on AA patient samples,
which is to attenuate NOTCH1IC expression following stimulation with anti-CD3ε and
anti-CD28. We recently showed that NOTCH1IC is elevated in patients with AA, and can
be found bound to the Tbx21 promoter, which codes for T-BET (Roderick et al., 2013).
In addition, we previously reported that NOTCH1 binds to and positively regulates the
ifng promoter in mice (Shin et al., 2006). These observations, together with the results of
our current study, prompt us to propose a unifying mechanism whereby PKCθ modulates
NOTCH1IC expression which, in turn, acts to regulate T-BET and IFNγ expression.
Solomou et al. (2006) also identified T-BET bound to the IFNγ promoter in patients with
AA. In this regard, therapeutic strategies which target PKCθ may prove to be
exceptionally beneficial in reducing IFNγ expression in AA patients, since the collective
data suggest it would decrease both T-BET and NOTCH1 expression, to effectively
interrupt Ifng transcription.
Accumulating experimental evidence supports the notion that PKCθ signaling is
complex and a strict requirement for its activity in CD4+ vs CD8+ T cells is likely
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context-dependent (Marsland and Kopf, 2008). PKCθ is differentially required by CD4+
and CD8+ T cells to convey survival signals, in vitro, with PKCθ-/- CD8+ T cells showing
a marked survival defect that only moderately affects PKCθ-/- CD4+ T cells (Saibil et al.,
2007). We demonstrated that using rottlerin to inhibit PKCθ activity in CD4+ and CD8+ T
cells 24 hours after stimulation resulted in differential effects on NOTCH1IC expression.
While NOTCH1IC expression in CD4+ T cells appeared to be less influenced by PKCθ
inhibition, CD8+ T cells required uninterrupted PKCθ activity to maintain NOTCH1IC
expression. How exactly PKCθ influences NOTCH1IC accumulation in CD8+ T cells is
under further investigation. TCR engagement, together with signals conveyed through the
CD28 co-receptor, triggers an activation cascade in T cells that requires PKCθ and
NOTCH1 (Shin et al., 2014). These amplified signals culminate in the nuclear
translocation of transcription factors belonging to the NF-κB family, which are normally
sequestered in an inactive complex in the cytosol of resting T cells. Other groups have
shown that translocation from the cytosol to the nucleus of one of these transcription
factors, c-Rel, is required for CD8+ T cell activation (Deenick et al., 2010). We
previously demonstrated that preventing NOTCHIC accumulation, using a
pharmacological inhibitor of NOTCH activation, markedly reduced the nuclear
accumulation and DNA-binding ability of c-Rel. Inhibiting NOTCHIC in murine T cells
also abrogated NOTCH1 and c-Rel binding to the Ifng promoter (Shin et al., 2006). Thus,
it is intriguing to speculate that inhibiting PKCθ may be acting upstream of NOTCH1 to
regulate IFNγ expression through this mechanism. The diminution of IFNγ production by
CD8+, but not CD4+ T cells, treated with rottlerin 24 hours after stimulation certainly
lends credence to this model.
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How PKCθ functions during T helper cell differentiation to mediate specific
immune responses has been the subject of debate. PKCθ has been shown to be
dispensable for Th1 immune reactions in response to pathogen infection (Marsland et al.,
2005; Marsland et al., 2004). On the other hand, PKCθ deficiency is protective against
autoimmune models with a pathogenic Th1 component, such as some the mouse models
of EAE, Th1 dependent antigen induced arthritis, and autoimmune myocarditis
(Anderson et al., 2006; Healy et al., 2006; Kwon et al., 2012; Marsland et al., 2007;
Salek-Ardakani et al., 2005; Tan et al., 2006). Studies suggest in some of these disease
models, especially EAE, PKCθ is also required to facilitate a pathogenic Th17 response
that is responsible for a significant portion of central nervous system destruction
(Rostami and Ciric, 2013). Th17 cells have been identified in AA patients; however, their
contribution to disease pathology has not been extensively explored (de Latour et al.,
2010). Nonetheless, whether PKCθ is important for development of Th1 or Th17 cells, or
both, its therapeutic targeting might provide a means of interrupting the differentiation of
these pro-inflammatory T cell subsets during AA progression.
A curative treatment for patients with AA is a bone marrow transplant (BMT)
from a donor who shares high genetic similarity, preferably a sibling. A significant
clinical obstacle to wider use of BMT, for treating AA patients as well as patients with
other hematological malignancies, is the risk of developing a serious post-transplant
condition known as graft-vs-host disease (GVHD). A recent elegant study identified
PKCθ as necessary to drive the pathogenesis associated GVHD (Valenzuela et al., 2009).
The authors suggested PKCθ may function to lower the threshold of T cell activation.
They further showed that in the presence of high affinity peptides or increasing doses of
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low affinity peptides, T cells deficient for PKCθ could be fully stimulated. In the absence
of PKCθ, T cells were unable to respond to the low affinity of the mismatched
MHC/antigens, and this suboptimal stimulation contributed to their inability to expand
and mediate disease in vivo. However, CD8+ T cells were able to bind high affinity
bacterial pathogens, presumably enabling them to overcome the lack of PKCθ, and clear
the infection. We noted a similar lack of T cell expansion in AA mice whose BMF was
induced with PKCθ-/- splenocytes (Roderick, unpublished). Furthermore, our observation
that PKCθ was specifically required in CD8+ T cells to mediate BMF is completely
consistent with the findings and interpretation provided by Valenzuela and colleagues
(Roderick, unpublished).
In this scenario inhibiting PKCθ, even for a relatively short duration, may deprive
T cells of the amplifying signal needed to respond productively to the low affinity
stimulus of self-antigens. Finally, it is possible that PKCθ may be regulating strength of
signal through the activation of NOTCH1, since studies showed NOTCH1 can regulate
TCR signal strength in thymocytes, as well as in mature T cells (Dongre et al., 2014; Izon
et al., 2001). Additional studies are required to understand the exact mechanisms at work
in our model and how they may be further extrapolated to patients with AA.
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Figure 2.1 T cells from AA mice express elevated pPKCθ
F1 hybrid mice were irradiated only (γIR controls) or induced with AA (BMF) and
harvested 17 days after disease induction. pPKCθ expression was determined in (A, C)
CD4+ and (B, D) CD8+ T cells isolated from (A, B) bone marrow and (C, D) spleen. Data
are the mean + SEM of three independent experiments. *P < 0.05, **P < 0.01; unpaired
student’s t test.
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Figure 2.2 PKCθ acts upstream of NOTCH1IC and IFNγ expression
We used flow cytometry to assess NOTCH1IC expression in WT (A) CD4+ and (C) CD8+
T cells treated with DMSO or rottlerin and in (B) CD4+ and (D) CD8+ T cells from
PKCθ-/- mice stimulated 48 hours with anti-CD3ε and anti-CD28. IFNγ expression in
DMSO- or rottlerin-treated (E) CD4+ and (G) CD8+ T cells or in (F) CD4+ and (H) CD8+
T cells from PKCθ-/- mice was also quantified using flow cytometry 48 hours after
stimulation with anti-CD3ε and anti-CD28. Data are the mean + SEM of three
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001; unpaired student’s t test.
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Figure 2.3 CD4+and CD8+ T cells show differential requirements for PKCθ
(A-D) WT T cells were stimulated up to 96 hours with anti-CD3ε and anti-CD28 and
cultured either continuously in the presence of DMSO or rottlerin (3µM; left panels),
cultured only for the first 24 hours in the presence of DMSO or rottlerin (center panels),
or cultured in the presence of DMSO or rottlerin that was added 24 hours after
stimulation (right panels). Using flow cytometry we assessed (A, B) NOTCH1IC
expression in (A) CD4+ and (B) CD8+ T cells at the indicated time points. We also used
flow cytometry to quantify (C, D) intracellular IFNγ in (C) CD4+ and (D) CD8+ T cells at
the time points indicated. Data are the mean + SEM of three independent experiments. *P
< 0.05, **P < 0.01, ***P < 0.001; two way ANOVA with Bonferroni post-test applied.
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Figure 2.4 T cells from treatment-naïve AA patients express elevated pPKCθ
We used flow cytometry to assess pPKCθ expression in unmanipulated (A) CD4+ and (B)
CD8+ T cells from healthy controls and from patients with AA who had not received
prior IST. (C,D) Peripheral blood mononuclear cells (PBMCs) from healthy controls or
from patients with AA were pre-treated either with DMSO or rottlerin (3µM) then
stimulated for 72 hours with anti-CD3ε and anti-CD28. We evaluated NOTCH1IC levels
in (C) CD4+ and (D) CD8+ T cells using flow cytometry. (E) We used ELISA to quantify
IFNγ secretion in supernatants of cultures treated as in C and D. n=3-6; Data are the
mean + SEM and represent three independent experiments; *P < 0.05, **P < 0.01,
***P < 0.001; (A, B) unpaired student’s t test, (C-E) one way ANOVA with Tukey’s
post-test applied.

	
  

68	
  

	
  
CHAPTER 3
NF-κB PLAYS A ROLE IN DISEASE PATHOLOGY OF APLASTIC ANEMIA
THROUGH THE REGULATION OF CXCR4

3.1 Introduction

Severe aplastic anemia (AA) is a rare acquired bone marrow failure (BMF)
syndrome where autoreactive T helper type-1 (Th1) lymphocytes are instrumental in
mediating disease. Circulating T cells from patients with AA express increased levels of
the Th1 transcriptional regulator, T-BET (Solomou et al., 2006), and intracellular
NOTCH1, which directly regulates T-BET expression in patient peripheral blood samples
(Roderick et al., 2013). Because approximately 30% of newly-diagnosed patients do not
respond to a single round of immunosuppressive therapy, it is imperative to investigate
other pathways in the autoreactive T cells that drive disease.
The NF-κB family of transcription factors are a family of homo- or heterodimers
that are comprised of 5 subunits: c-Rel, p65 (RelA), RelB, p50 (NF-κB1) and p52 (NFκB2). p50 and p52 are processed by the precursors p105 and p100, respectively. Each
homodimer or heterodimer has distinct expression patterns and regulatory functions,
depending on the cell type (Gilmore, 2006). In T cells, NF-κB is activated canonically
after T cell stimulation. After T cell receptor activation in T cells, active PKCθ
phosphorylates Carma1, which is able to complex with Malt1 and BCL10 to form the
CBM complex. After formation of the signaling complex, NF-κB is released from IκB
following its phosphorylation and subsequent degradation. NF-κB is able to then
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translocate into the nucleus and mediate downstream signaling associated with T cell
activation and differentiation such as expression of IL-2, CD25, IL-2Rα, and IFNγ
(Vallabhapurapu and Karin, 2009). Dysregulation of NF-κB signaling has been
associated with numerous autoimmune diseases, including rheumatoid arthritis, systemic
lupus erythematosus, type I diabetes, multiple sclerosis, and inflammatory bowel disease
(Sun et al., 2013).
Chemokines are small molecules that are able to influence the motility of cells
through binding to their cognate chemokine receptor. CXCR4 is a chemokine receptor
that is constitutively expressed on T cells, and its main role in T cells is to drive
migration along gradients of SDF-1, its chemokine ligand. CXCR4 can act as a
costimulator of T cell proliferation and differentiation through its interaction with the
TCR (Kumar et al., 2006; Molon et al., 2005). CXCR4 has also been shown to be highly
overexpressed in many cancers, including human breast cancer cell lines and primary and
metastatic breast tumors, ovarian cancer, prostate cancer, and melanoma (Hall and
Korach, 2003; Kim et al., 2008; Muller et al., 2001; Taichman et al., 2002). Additionally,
NF-κB signaling has been shown to directly regulate CXCR4 expression to promote
breast cancer migration and metastasis (Helbig et al., 2003). Since NF-κB is important in
T cell activation and differentiation and has been shown to drive CXCR4 expression and
chemotaxis in cancer migration and metastasis, we asked if NF-κB drove AA
pathogenesis through an upregulation of CXCR4.
In this study, we show that NF-κB signaling is necessary for the development of
AA and inhibiting its function ameliorates disease. When we blocked NF-κB signaling by
using p50-/- to induce AA in our mouse model, we found that donor cells were unable to
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expand in the bone marrow, spleen and peripheral blood of the recipient mice. Treatment
of AA mice with DHMEQ, a nuclear transportation inhibitor of NF-κB, reduced the
levels cytokines associated with AA in the serum. We could also reduce Notch1IC
expression in T cells that were infiltrating the bone marrow of AA mice through NF-κB
signaling inhibition. When we examined CXCR4 expression in AA mice compared to
irradiation control mice, we found that AA mice had increased expression of CXCR4 on
the bone marrow infiltrating T cells and when NF-κB signaling is blocked in AA mice,
CXCR4 expression is reduced. Also, when T cells are treated with Bay-11, a IκBα
degradation inhibitor and stimulated in a mixed lymphocyte reaction (MLR), chemotaxis
in response to SDF-1 is severely reduced. Taken together, these data show that NF-κB
drives AA progression through T cell activation and through not only a reduction in T
cell activation, but also by upregulation of CXCR4 expression.

3.2 Results

3.2.1 Blocking NF-κB signaling abrogates AA disease progression

Because NF-κΒ has been shown to be important in T cell signaling and activation,
and it has been shown to be dysregulated in many autoimmune diseases, we wanted to
see if it was necessary to drive pathogenesis of AA (Vallabhapurapu and Karin, 2009).
To pharmacologically inhibit NF-κB signaling in vivo, we used two inhibitors of NF-κB
that block signaling a different points in the pathway. The first inhibitor, Bay-11, is an
irreversible inhibitor of cytokine-inducible IκBα phosphorylation, therefore, it acts by
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blocking the release of NF-κB subunits from their cytoplasmic sequestration (Pierce et
al., 1997). The other inhibitor, Dehydroxymethylepoxyquinomicin or DHMEQ is a new
NF-κB inhibitor that is a 5-dehydroxymethyl derivative of a novel compound
epoxyquinomicin and prevents nuclear translocation of NF-κB by sequestering it in the
cytoplasm (Matsumoto et al., 2000).
For these studies, we induced mice with AA as described previously, and one
hour after disease induction we treated mice with DHMEQ (30 mg/kg/day), Bay-11 (5
mg/kg/every other day), vehicle only (DMSO), or we induced recipient mice with p50deficient donor splenocytes (B6.Cg- Nfkb1

tm1Bal

/J). On day 17 post induction, mice were

humanely euthanized to assess disease severity. Pharmacological inhibition of NF-κB in
AA mice, with both DHMEQ and Bay-11 and genetic deletion of the p50 subunit in
donor cells resulted in significantly increased bone marrow cellularity when cells were
enumerated using trypan blue exclusion (Figure 3.1A) and when assessed by H & E
staining (Figure 3.1B). Treatment of AA mice by blocking NF-κB signaling also
increased the numbers of circulating white and red blood cells (Figure 3.1, C and D)
compared with AA mice in all cases, therefore ameliorating the peripheral pancytopenia
associated with disease.
To see if the amelioration of disease symptoms was due to a reduction of
pathogenic T cell infiltration into the bone marrow, we used flow cytometry to look at the
percentages of CD4+ and CD8+ T cells in the bone marrow. Compared to AA mice that
have a large percentage of T cells in the bone marrow at day 17 P.I., mice treated with
DHMEQ, Bay-11 and p50-/- AA mice have significantly reduced numbers of CD4+ and
CD8+ T cells in the bone marrow, at levels comparable to γ-IR control mice (Figure
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3.1E). Next we asked whether therapeutic administration of Bay-11 prolonged the
survival of AA mice. For these experiments, we induced mice with AA and treated mice
with Bay-11 (5 mg/kg/every other day) or vehicle only (DMSO) from day 5 to 17 postdisease induction at which time treatment was discontinued and disease progression was
monitored. Compared with DMSO-treated mice for which the median survival time was
19.5 days, mice treated with Bay-11 showed a remarkable survival benefit with four of
seven mice fully rescued from lethal BMF (P < 0.01; Figure 3.1F). We also looked at the
survival potential of AA mice induced with p50-/- splenocytes. Compared to mice induced
with WT splenocytes who succumbed to disease on a median day of 20 post induction,
mice induced with p50-/- cells did not succumb to disease and survived indefinitely
(p=0.0339, Figure 3.1G). Taken together, these data demonstrate that NF-κB drives
disease progression of AA.

3.2.2 Mice induced p50-/- deficient cells do not develop disease because of a failure of
cells to expand

Because AA mice induced with p50-/- splenocytes never develop disease, we
asked if the p50-deficient donor cells were able to react to alloantigens and expand in the
recipient AA mice. To ask this question, mice were induced with AA using WT or p50-/splenocytes and were harvested on days 10, 13, 15 or 17 post disease induction and donor
cells were enumerated by assessing the percentage of H2kb+H2kd- cells in the bone
marrow, spleen and peripheral blood by flow cytometry. In the bone marrow, there is a
very low presence of donor cells in p50-/- AA mice present throughout the disease course;
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however, on day 10 post induction, about 20% of cells in the bone marrow in WT AA
mice are donor derived, while by day 17, almost half of the cells in the WT AA mice of
donor origin (Figure 3.2A). There are slightly more donor cells in the spleen (Figure
3.2B) and peripheral blood (Figure 3.2C) over the disease course in p50-/- induced AA
mice, however, the amount is significantly reduced compared to WT induced animals.
These data infer that p50-/- never become activated enough to clonally expand to a point
where they can mediate migration to the bone marrow and drive disease.

3.2.3 Inhibiting NF-κB nuclear localization decreases Th1 associated cytokine
secretion in the plasma of AA mice

Plasma from mouse models of AA and human patients contain high amounts of
Th1 associated cytokines (such as IFNγ and TNF) compared with healthy controls
specimens (Young et al., 2008). NF-κB signaling has been shown to regulate the
production of proinflammatory and Th1 associated cytokines in T cells (Vallabhapurapu
and Karin, 2009). To see if we could ablate high cytokine levels in the plasma of AA
mice by blocking NF-κB activation, we treated AA mice with DHMEQ or DMSO as
described above. On day 17 post induction, mice were humanely sacrificed and plasma
was collected from induced mice. To measure the concentration of circulating cytokines
present in the plasma, a Cytometric Bead Array (CBA; BD Biosciences) was done to
measure proinflammatory cytokines (IL-2 and IL-6), Th1 cytokines (TNF and IFNγ), Th2
(IL-4), Th17 (IL-17a) and anti-inflammatory (IL-10) cytokines. When mice were treated
with the NF-κB inhibitor DHMEQ, the proinflammatory cytokines (IL-2 and IL-6; Figure
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3.3, A and B) and Th1 cytokines (TNF and IFNγ; Figure 3.3, C and D) were reduced in
the serum of AA mice compared with DMSO treated controls. When we examined the
levels of cytokines associated with other T helper subtypes, such as IL-4 (Th2), IL-17a
(Th17), and IL-10 (Treg/anti-inflammatory), there was no difference in levels of cytokine
production between DMSO treated and DHMEQ treated animals (Figure X, E-G). This
implies that NF-κB signaling is needed for the production of Th1 associated cytokines in
AA, and blocking the activation of NF-κB suppresses the cytokine storm associated with
disease.

3.2.4 Notch1IC is reduced in CD4+ cells infiltrating the bone marrow of AA mice
when NF-κB signaling is targeted

Our lab has shown that Notch1 signaling is necessary for driving AA disease
pathogenesis (Roderick et al., 2013). Also, we have also shown that Notch and NF-κB
signaling interact to drive T cell activation (Shin et al., 2006; Shin et al., 2014). Because
of this evidence, we hypothesized that blocking NF-κB signaling would reduce Notch1IC
levels in AA mice. In mice treated with Bay-11 or induced with p50-/- splenocytes, the
percentage of Notch1IC in both CD4+ and CD8+ T cells in the bone marrow is
significantly decreased compared to AA controls on day 17 post induction (Figure 3.4A).
When Notch1IC expression was examined on a per cell basis, however, Notch1IC was
decreased in the CD4+ gate in the bone marrow only from mice induced with p50-/splenocytes compared to AA controls, and did not decreased in any mice where NF-κB
signaling was inhibited when CD8+ T cells were analyzed (Figure 3.4B). While there was
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a decrease in the percentage of Notch1IC expressing cells in Bay-11 treated and p50-/induced AA mice, DHMEQ treated AA mice have similar or higher levels of Notch1IC,
which was not expected (Figure 3.4, A and B). This difference in Notch expression
between the groups treated with different NF-κB signaling inhibitor could be due to the
fact that various components of the NF-κB pathway are being targeted differently
depending on which method is used.

3.2.5 CXCR4 is differentially regulated in mice induced with AA compared to
irradiation controls

The role of CXCR4/SDF-1 signaling in the progression and dissemination of
hematopoietic malignancies and autoimmune diseases have been well documented
(Domanska et al., 2013). However a role for CXCR4 in the pathogenesis of the
autoimmune disease Aplastic Anemia has not been previously explored. First, we
assessed both the gene and protein expression of CXCR4 in T cells from the spleen and
BM of mice induced with AA. On day 17 post-disease induction, the transcript levels of
Cxcr4 in T cells isolated from spleen and BM of AA mice were similar to those found in
T cells from spleens of control mice that had only been irradiated (Figure 3.5A).
However, the protein expression of CXCR4 was significantly higher in spleen CD4+ T
cells and BM-infiltrating CD4+ and CD8+ T cells of AA mice compared with spleen T
cells of γ-irradiation control mice (Figure 3.5, B and C). Furthermore, compared with
control mice, AA mice expressed CXCR4 at a significantly higher percentage in CD4+
and CD8+ T cells from both the spleen and the bone marrow (Figure 3.5D). Notably, of
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those T cells that migrated to the bone marrow in AA mice, CD8+ T cells showed a
higher expression of CXCR4 than CD4+ T cells (Figure 3.5E). These results document
that CXCR4 expression on CD4+ and CD8+ T cells in mice induced with AA is highly
upregulated, especially on CD8+ T cells resident in the bone marrow.

3.2.6 Inhibition of NF-κB reduces expression of CXCR4 in T cells and abrogates
their chemotaxis to SDF-1α

Studies have shown that NF-κB regulates the expression of CXCR4 to promote
migration and metastasis in a variety of malignancies such as breast cancer (Helbig et al.,
2003). Therefore, we wanted to see if blocking NF-κB signaling in our mouse model of
AA would reduce CXCR4 expression. Therefore, we induced mice with AA and treated
them with NF-κB inhibitors as described above. In Bay-11-treated AA mice, we detected
CXCR4 in a significantly lower percentage of BM-infiltrating CD4+ and CD8+ T cells
(Figure 3.6A) and the expression of CXCR4 on a per cell basis was significantly reduced
in these cells compared with diseased animals (Figure 3.6B). In CD4+ infiltrating bone
marrow T cells, however, AA mice treated with DHMEQ and p50-/- AA mice had no
difference of CXCR4 expression on their infiltrating T cells. Conversely, CD8+ bone
marrow T cells from mice where NF-κB signaling was inhibited by all methods had a
decrease in both the percentage of CXCR4+ cells and a decreased of the expression of
CXCR4 on a per cell basis (Figure 3.6, A and B). These data show that in CD8+ T cells,
CXCR4 expression can be reduced by inhibiting NF-κB signaling.

	
  

77	
  

	
  
We next asked whether inhibition of NF-κB signaling could result in a reduction
of SDF-1α mediated chemotaxis. To do this, we examined expression of CXCR4 in T
cells activated in conditions resembling the interactions occurring in vivo between donor
and recipient cells in our AA model. We set up a mixed lymphocyte reaction (MLR)
culture in which bulk splenocytes from C57BL/6 mice were co-cultured with BMDCs
from F1 hybrids (BALB/c X C57BL/6) and treated cultures with Bay-11 (1 µM) or
vehicle only (DMSO) at the time of plating. We then examined the expression of CXCR4
using flow cytometry over a 12 day period. Bay-11-treated CD4+ T cells showed
significantly lower levels of CXCR4 on days 6 and 8 of culture compared with DMSOtreated T cells (Figure 3.6C) Meanwhile, compared with DMSO-treated T cells, Bay-11treated CD8+ T cells also displayed significantly lower levels of CXCR4 at days 6, 8 and
10 (Figure 3.6D). We then took cells from the MLR cultures on day 8 of culture and
subjected those cells to a chemotaxis assay towards SDF-1α. We found that Bay-11treated CD4+ and CD8+ T cells exhibited a significantly lower chemotactic response to
SDF-1α compared with control T cells treated with vehicle only (Figure 3.6, E and F).
These findings indicate that inhibition of NF-κB reduces expression of CXCR4 in CD4+
and CD8+ T cells both in vitro and in vivo and affects their ability to migrate in response
to SDF-1α in vitro.

3.3 Discussion

For the first time, we describe a role for NF-κB signaling in driving the
immunopathogenesis of Aplastic Anemia. Using our mouse model of AA (Roderick et
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al., 2013), we can ameliorate progression of AA using two inhibitors of NF-κB signaling,
DHMEQ and Bay-11, and through genetic ablation of the p50 subunit of NF-κB in our
donor cells. p50-/- splenocytes fail to expand in the AA recipient mice in both the bone
marrow, spleen, and peripheral blood. Also, DHMEQ treatment reduces the secretion of
Th1 associated cytokines in the serum of AA mice. Besides its classical role in T cell
activation and differentiation, NF-κB has been shown to directly regulate CXCR4
expression in breast cancer, thus increasing their mobility and metastasis (Helbig et al.,
2003). Therefore, we looked at the expression of CXCR4 in our mouse model of AA and
found that CXCR4 was upregulated on BM-infiltrating T cells from AA mice, and was
most highly expressed on the CD8+ T cells from the bone marrow. Finally, we could
reduce the expression of CXCR4 by blocking NF-κB signaling both in vitro and in vivo,
and could reduce the SDF-1α migration potential of T cells using the NF-κB signaling
inhibitor, Bay11.
Our results clearly show that NF-κB signaling drives the pathogenesis of Aplastic
Anemia. We used three different methods to abrogate NF-κB signaling. We used two
pharmalogical inhibitors: Bay-11, an inhibitor that blocks the degradation of IκB and the
subsequent translocation of NF-κB into the nucleus, and DHMEQ, an inhibitor that
blocks the translocation of NF-κB into the nucleus through unknown methods. We also
used cells from animals that had a genetic knockout of the p50 subunit of NF-κB. Not
surprisingly we are able to concretely show that signaling through this pathway is
necessary for AA pathogenesis by using these three methods. Since NF-κB signaling is
important for T cell stimulation and Th1 differentiation, its important role in AA
pathogenesis was expected (Vallabhapurapu and Karin, 2009). Also, because our lab has
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shown that both the Notch signaling pathway and PKCθ pathway are necessary for AA
disease progression (Roderick et al., 2013), and both these pathways have been shown to
interact with NF-κB to drive T cell activation, our results fit nicely with the notion that
abberant T cell signaling downstream of the TCR in response to self antigen is driving
disease (Shin et al., 2006; Shin et al., 2014; Sun et al., 2000).
Since the NF-κB signaling pathway regulates multiple downstream processes in T
cells, we wanted to elucidate which cellular mechanisms NF-κB could be affecting to
regulate disease. NF-κB signaling has been shown to be responsible for regulating T cell
activation and proliferation through direct regulation of cytokine production
(Lamhamedi-Cherradi et al., 2003), and we were able to abrogate cytokine production in
our model when AA mice were treated with the NF-κB inhibitor, DHMEQ. Additionally,
we show here that genetically deleting the p50 subunit in donor cells ameliorate disease
due to a failure of donor cells to expand and proliferate in the recipient while in vitro
studies show that p50-/- T cells are able to produce similar amounts of IL-2 and IFNγ
when stimulated through the TCR and CD28 co-receptor (data not shown). Studies have
shown that while T cells deficient in c-Rel intrinsically have defects in IL-2 production
and Th1 cytokine production in a diabetes model, the inability of p50-/- T cells to mediate
disease was not through direct cytokine production, but was a through an indirect
reduction in autoreactive T cell activation via APC stimulation (Lamhamedi-Cherradi et
al., 2003). However, further discovery into the differential roles of the NF-κB subunits in
different cell types responsible in AA development is required.
Interactions between the NF-κB and Notch signaling pathways have been shown
to be important in T cell activation (Shin et al., 2006; Shin et al., 2014). Therefore, we
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wanted to see if a decrease in NF-κB signaling correlated with a decrease in Notch1
activation in our AA mouse model, where Notch signaling has been shown to play an
important role (Roderick et al., 2013). We did see a decrease in the percentage of cells
expression Notch1IC in both CD4+ and CD8+ T cells of the bone marrow when we treated
cells with Bay-11 or induced mice with p50-/- cells. However, we did not see a decrease
in Notch1IC when AA mice were treated with DHMEQ. This could be because of the
method with which DHMEQ blocks NF-κB. It is not well characterized, but DHMEQ is
thought to block NF-κB by blocking its nuclear localization signal (Ariga et al., 2002).
Along with NF-κB, DHMEQ could also be affecting Notch1IC translocation, and
somehow causing an accumulation of Notch1IC in the cytoplasm that is unable to be
degraded. However, further studies on the mechanism of inhibition of DHMEQ need to
be performed to understand the mechanism of inhibition.
The chemokine receptor CXCR4 is responsible for chemotaxis of cells along
gradients of SDF-1, which is mainly secreted in the bone marrow (Viola et al., 2006).
Many metastatic cancers, which require motility of cancerous cells to sites such as the
bone marrow, also have high expression of CXCR4 (Helbig et al., 2003). Since SDF-1 is
highly expressed in the bone marrow, it was not surprising that T cells from AA mice that
have migrated to the bone marrow express higher levels of CXCR4 compared to splenic
resident T cells from irradiated controls. Also, we found that CD8+ T cells that infiltrate
the bone marrow express higher amounts of CXCR4 compared to CD4+ T cells that
infiltrate the bone marrow. While we cannot assume that higher expression of CXCR4
contributes to T cell pathogenicity in this context, it is interesting to speculate that the
high expression of CXCR4 is one of a multitude of contributing factors that cause CD8+
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T cells to play such an important role in our model of AA and human disease (Young et
al., 2008). It is probably through the aberrant expression of CXCR4 that T cells are able
to home to the bone marrow in response to SDF-1 and mediate damage to the resident
stem and progenitor cells. However, since CXCR4 has been shown to be a costimulatory
molecule during TCR signaling, it could be helping to augment T cell activation in this
context (Kumar et al., 2006; Molon et al., 2005).
NF-κB signaling has been shown in breast cancer models to directly regulate the
expression of CXCR4, and this contributes directly to the metastatic and motile
tendencies of secondary tumors both in vitro and in animal tumor models (Helbig et al.,
2003). Notably, in AA mice where NF-κB signaling was inhibited, we detected a
significant reduction of the percentage of BM-infiltrating CD8+ T cells expressing
CXCR4, and the expression of CXCR4 on these cells was also significantly decreased.
We were able to mirror this observation using in vitro MLR cultures. Using this method,
we were able to see a decrease in CXCR4 expression in both CD4+ T cells and CD8+ T
cells when cultures were treated with Bay-11. We didn’t the same robust decrease in
CXCR4 expression on CD4+ T cells from the bone marrow of our AA mice, however,
this could be due to differing kinetics of expression between the two systems or CD4+ T
cells in the bone marrow of AA mice could downregulate their CXCR4 expression upon
entrance to the bone marrow. Both of these possibilities would have to be further
researched.
Using a chemotaxis assay, we are able to show that inhibiting NF-κB signaling
not only decreases CXCR4 expression, but it also reduces the chemotactic ability of these
cells in response to SDF-1α. This fits in with our hypothesis that CXCR4 expression is
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causing T cells to mobilize to the bone marrow where this is a large expression SDF-1α
in normal physiological instances. However, levels of SDF-1 have not been explored in
AA patient bone marrow aspirates, but it would be interesting to see if they expressed
higher levels of SDF-1. This could partly answer why T cells home to the bone marrow
to mediate destruction in AA.
Based on these studies, we provide clear evidence that NF-kB signaling
contributes to disease pathology in AA by modulating CXCR4-mediated migration of
CD4+ and CD8+ T cells to the BM. Blocking NF-κB signaling may not only help decrease
CXCR4 mediated migration, but it may also help quell the pathogenic T cell activation
that is a hall mark of this disease. The multimodal targeting of NF-κB signaling inhibitors
makes them an attractive therapy. However, studies must be done to see if there would be
pan-suppressive effects to the immune system by blocking this important signaling
pathway. CXCR4 inhibitors may also be an attractive candidate. However, it may cause
pathogenic T cells to home away from the bone marrow, causing possible tissue
destruction in other organs through cytokine storm. Further studies on both types of
inhibitors could prove invaluable in the search for a cure.
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Figure 3.1 Pharmacologically inhibiting NF-kB inhibition in a mouse model of AA
attenuates disease
Mice were induced with AA and treated with DHMEQ, Bay-11, or induced with p50-/splenocytes as described above. On day 17 post-induction, mice were harvested and (A)
total bone marrow cellularity was determined using trypan blue exclusion. (B)
Representative hematoxylin and eosin staining of sterna of AA mice. Magnification=20x.
Circulating (C) white blood cells (WBC) and (D) red blood cells (RBC) were measured.
(E) Percentages of CD4+ and CD8+ T cells infiltrating the bone marrow were determined
using flow cytometry. (F) Kaplan–Meier survival estimates of AA mice induced with
disease and treated with DMSO (n=4) or Bay11 (n=7) beginning on day 5 post-diseaseinduction and continuing until day 17 post-disease-induction (p<0.01) and (G) Kaplan–
Meier survival estimates of AA mice induced with WT (AA; n=4) or p50-/- splenocytes
(p50-/- AA; n=7) , p=0.0339. Data are the mean plus SEM and analyzed using one way
ANOVA plus Tukey post test or log rank test for survival estimates *, P < 0.05; **, P <
0.01; ***, P < 0.001.
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Figure 3.2 Donor cells in p50-/- induced AA mice do not expand compared to donor
cells in WT induced AA mice
F1 recipient mice were induced with WT or p50-/- C57BL/6 bulk splenocytes and mice
were harvested at day 10, 13, 15, and 17 post induction. Donor cells were tracked by flow
cytometry by gating on H2kb+H2kd- cells in the (A) bone marrow, (B) spleen, and (C)
peripheral blood of recipient mice. n=3; data are the mean +/- SEM of three independent
experiments. *p<0.05, **p<0.01, ***p<0.001; Two Way ANOVA and Bonferroni post
test.
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Figure 3.3 Inhibiting NF-κB nuclear localization decreases Th1 associated cytokine
concentrations in the plasma of AA mice
AA mice treated with DMSO (BMF Control) or treated with DHMEQ were induced and
circulating cytokines were assessed using the Cytometric Bead Array Multiplex Kit (BD
Biosciences). Cyotkines assessed: (A) IL-2, (B) IL-6, (C) TNF, (D) IFNγ, (E) IL-4, (F)
IL-17A, and (G) IL-10. n=4 in each group. *p<0.05, **p<0.01, ***p<0.001; unpaired
student t test.
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Figure 3.4 Intracellular Notch1 is reduced in the bone marrow bone marrow
infiltrating T cells when NF-κB signaling is targeted
Notch1IC were analyzed using flow cytometric methods in CD4+ or CD8+ T cells from
the bone marrow of mice induced with AA. (A) Percentage of Notch1IC and (B) Median
fluorescent intensity (MFI) were determined. n=3-15 animals. Data represents the mean
plus SEM analyzed with One Way ANOVA and Tukey’s post test.. *p<0.05, **p<0.01,
***p<0.001.
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Figure 3.5 CXCR4 protein expression is upregulated on T cells in mice with Aplastic
Anemia
	
  
	
  Mice were induced with AA and T cells were isolated from the bone marrow and spleen.
(A) Relative expression of cxcr4 transcript in spleen and bone marrow T cells from
diseased mice was determined by qPCR and compared to expression in spleen T cells
from γIR-treated mice; n=8. (B) Median fluorescence intensity (MFI of CXCR4 on
spleen and bone marrow T cells from diseased animals was determined by flow
cytometry; n=8. (C) Representative comparative histogram of CXCR4 MFI of spleen and
bone marrow T cells in diseased mice. (D) Percentage of CXCR4 expressing T cells as
assessed by flow cytometry in T cells from AA mice. (E) MFI of CXCR4 expression on
T cells from the bone marrow of AA mice. Data represent the mean plus SEM and were
analyzed by one way ANOVA plus Tukey post test (A,B, and D), or by unpaired student
t test (E). *, P < 0.05; **, P < 0.01; ***, P < 0.001
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Figure 3.6 Blocking NF-kB decreases CXCR4 expression in T cells and abrogates
their chemotaxis
Mice were induced with AA and treated with NF-κB inhibitors as described above. The
(A) percentage of CXCR4 T cells and the (B) MFI of CXCR4 on T cells resident in the
bone marrow was analyzed by flow cytometry, n=8. Bulk splenocytes from C57BL/6
mice were treated with DMSO or Bay11 (1 mM) and co-cultured with bone marrowderived DCs from F1 hybrids for 12 days. CXCR4 expression was assessed using flow
cytometry in (C) CD4+ and (D) CD8+ T cells; n=3. T cells isolated on day 8 from cocultures (as above) were seeded into a chemotaxis assay with 0 ng/ml or 100 ng/ml of
SDF-1 was coated onto lower chamber wells. The chemotaxis index ratio was calculated:
(number of cells present in the 100 ng/ml SDF-1 chamber/number of cells present in the
0 ng/ml SDF-1 chamber) for DMSO- or Bay11-treated (E) CD4+ and (F) CD8+ T cells;
n=3. Data are the mean plus SEM and were analyzed using Two Way ANOVA with
Bonferroni post test (A,B) or two-tailed unpaired student t test (C,D). *, P < 0.05; **, P <
0.01; ***, P < 0.001.
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CHAPTER 4
MICRORNA-155 DRIVES THE PROGRESSION OF APLASTIC ANEMIA
THROUGH REGULATION OF PD-L1

4.1 Introduction

MicroRNA-155 (miR-155) is a non-coding RNA in an exon that is transcribed from
the B-cell Integration Cluster (BIC) gene located on chromosome 21 in humans and
chromosome 16 in the mouse genome (Tam, 2001). This region of BIC is conserved
across human, mouse and chicken genomes and is highly expressed in lymphoid organs
across species, implying an evolutionarily conserved function (Lagos-Quintana et al.,
2002). miR-155 signaling has been shown to play important roles throughout the immune
system, including roles in hematopoiesis, innate immunity, neoplasia and viral infections
(Bhela et al., 2014; Chen et al., 2014; Dudda et al., 2013; Jiang et al., 2014; O'Connell et
al., 2008; Romania et al., 2008). Additionally, miR-155 has been implicated in the
development of inflammation and other adaptive immune responses (Lodish et al., 2008;
O'Connell et al., 2008). For example, miR-155 has been shown to play an important role
in T and B cell responses, and miR- 155 levels increase upon their activation (Thai et al.,
2007). In B cells, miR-155 is important for the formation of germinal centers, class
switching of antibodies, and somatic hypermutation (Dorsett et al., 2008; Rodriguez et
al., 2007; Thai et al., 2007; Vigorito et al., 2007).
In T cells, miR-155 has been shown to play an important role in influencing the
differentiation of naïve T cells into different helper subtypes. T cells deficient in
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BIC/miR-155 skew towards a Th2 phenotype through their inability to produce IFNγ and
IL-12 (Rodriguez et al., 2007). miR-155 deficiency has also been shown to reduce the
number of Tregs in the periphery and thymus of mice, but it does not reduce their
suppressive capacity (Lu et al., 2009). Also, miR-155-/- cells produce less IL-17a, and
miR-155-/- mice do not develop EAE (O'Connell et al., 2010). Additionally, patients with
rheumatoid arthritis (RA) have higher levels of miR-155 in their synovial fluid than
patients with osteoarthritis (Spoerl et al., 2013). Also in RA patients, miR-155 has been
shown to target CTLA-4, a negative regulator of T cell activation (Spoerl et al., 2013).
These data suggest that miR-155 could be acting to enhance T cell activation, and the
dysregulation of miR-155 could cause aberrant T cell signaling in autoimmune diseases
through faulty regulatory mechanisms.
Because miR-155 plays a role in Th1 differentiation and autoimmune disease, we
sought to see if miR-155 plays a role in driving Aplastic Anemia. Using our AA mouse
model and miR-155-/- mice as the source of our donor splenocytes, we found that miR155 was necessary for AA pathogenesis. Also, we found that miR-155 expression is
decreases Notch1 activation, and miR-155 targets PD-L1 expression in T cells causing a
decrease of iTreg cells in our AA mice.
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4.2 Results

4.2.1 miR-155 expression is increased when mice are induced with Aplastic Anemia

Because AA is driven by Th1 cells and miR-155 has been shown to play a role in
Th1 differentiation, we hypothesized that miR-155 would be highly expressed in our
mouse model of AA. To examine the levels of miR-155, AA was induced in our mouse
model as described above. Seventeen days after disease induction, we harvested bone
marrow from recipient mice and quantified the miR-155 expression using qRT-PCR.
Compared to irradiated controls, AA mice had significantly more miR-155 expressed in
the bone marrow (Figure 4.1A). In the spleen, T cells from irradiated controls and spleen
cells from AA mice were also analyzed for miR-155 expression. Like in the bone
marrow, T cells from mice induced with AA had significantly higher amounts of miR155 compared to the irradiation controls (Figure 4.1B). We next took peripheral blood
samples from AA patients without prior IST treatment and compared the miR-155
expression to T cells from healthy donors. While there was no significant different in
miR-155 expression between the two groups, 2 out of 3 patients samples had increased
miR-155 expression compared to the mean of healthy donor samples (Figure 4.1C).
These data confirms that miR-155 levels are increased in our mouse model of AA.
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4.2.2 miR-155 is necessary for the development of Aplastic Anemia

Because miR-155 plays an important role in autoimmune diseases with a strong
Th1 component such as EAE and RA, we wanted to see if miR-155 was necessary to
drive AA (O'Connell et al., 2010; Spoerl et al., 2013). To achieve this goal, we used
splenocytes from WT or miR-155-/- mice (B6.Cg-Mir155 tm1.1Rsky/J; Jackson Laboratories)
and induced AA as described above. AA mice induced with miR-155-/- splenocytes had
increased bone marrow cellularity as assessed using trypan blue exclusion (Figure 4.2A)
and increased white blood cells (Figure 4.2B) and red blood cells (Figure 4.2C)
compared to WT BMF controls confirming that miR-155 is required for the development
of AA symptoms in our mouse model.
Next, we wanted to see if miR-155 was needed for the autopathogenic T cell
response in our model. When we examined T cell infiltration into the bone marrow using
flow cytometry. miR-155-/- AA mice had a significantly reduced level of both CD4+
(Figure 4.2D) and CD8+ (Figure 4.2E) T cells present in the bone marrow, and the T cell
levels were comparable to irradiation controls. Finally, we induced AA mice with WT
splenocytes or miR-155-deficient splenocytes and performed a survival study. We found
that while WT mice succumb to disease at a mean day of 21 post induction, miR-155
survived indefinitely, and this difference was significant (Figure 4.2F; p<0.01). These
data suggest that miR-155 is necessary in driving the pathogenesis of Aplastic Anemia.
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4.2.3 AA mice induced with miR-155-deficient cells express less Notch1IC in the T
cell compartment.

Notch signaling has been shown to drive the pathogenesis of Aplastic Anemia
(Roderick et al., 2013). Therefore, we wanted to see if deleting miR-155 in our donor
cells decreased Notch1IC in the infiltrating T cells in our mouse model. To answer this
question, we induced our AA mice with WT or miR-155-/- cells and on day 17 post
disease induction, we examined the Notch1IC expression using flow cytometry. In the
bone marrow of mice induced with miR-155-/- splenocytes, the Notch1IC expression is
significantly decreased in the CD8+ T cells and are present in these cells at levels similar
to irradiation controls (Figure 4.3B). While not significant, Notch1IC is reduced in CD4+
T cells infiltrating the bone marrow (Figure 4.3A). In the spleen of AA induced mice,
Notch1IC expression in both CD4+ and CD8+ T cells is significantly reduced compared to
the WT BMF induced mice, and the level of Notch1IC in these cells is also similar to
irradiation controls (Figure 4.3, C and D). These data suggest that miR-155 is needed for
activation of Notch1 in our mouse model of AA, and this could be one mechanism of
how miR-155 is driving the pathogenesis of T cells in the disease.

4.2.4 Notch1IC expression is reduced in mir-155-deficient CD4+ T cells compared to
WT CD4+ T cells

To further understand the temporal regulation that miR-155 may have on Notch1
activation, we use MLR cultures as a way to simulate activation of CD4+ T cells in our
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mouse model of AA. We used BMDC from an F1 hybrid donor and cultured them with
CD4+ T cells that were isolated from WT or miR-155-/- spleens. We cultured these cells
for 8 days and examined Notch1IC expression using flow cytometry. Both WT and miR155-deficient cultures have the same percentage of Notch1IC positive CD4+ T cells
(Figure 4.4A) over the entire 8 day cultures. However, in WT CD4+ T cells, Notch1IC
expression on a per cell basis (MFI) peaks on day 4 and drops back to initial levels on
day 6 and 8. In miR-155-/- CD4+ T cells, however, Notch1IC levels never peak on day 4,
and the day 4 Notch1IC expression is significantly decreased compared to WT CD4+ T
cells (Figure 4.4B).
To see if miR-155 is upstream of Notch activation, or if Notch activation may
also be important in driving miR-155 expression, we set up MLR cultures with F1
derived BMDC and WT CD4+ T cells as described above and treated the CD4+ T cells
with DMSO or GSI 30 minutes prior to plating. We observed that GSI significantly
decreased miR-155 expression over the 8 day culture as compared to cultures where
CD4+ T cells were treated with DMSO (Figure 4.4C). The kinetics of activation, however
seemed to be similar between the two cultures. While both cultures have a peak of miR155 expression on day 4, GSI treated CD4+ T cells do not reach the same levels of miR155 as DMSO treated cells. These data suggest that after T cell activation, both miR-155
and Notch activation regulate each other’s expression.
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4.2.5 PD-L1 expression is significantly higher in miR-155 deficient CD4+ T cells than
WT CD4+ T cells

Next, we wanted to identify some potential targets of miR-155 that could be
important in AA pathogenesis. When miR-155 was put into the microRNA target
predictor, TargetScan, one potential target was PD-L1. Two sites in the human 3’ UTR of
PD-L1 (gene name CD274) had 7 sites of perfect complementarity to the miR-155 seed
sequence (Figure 4.5.A). PD-L1 can block T cell proliferation on corresponding T cells
by engaging its receptor, programmed death ligand 1, or it can also inhibit T cell
stimulation intrinsically by binding the CD80 molecule (B7-1) on APCs and blocking the
engagement of CD28 with CD80 (Butte et al., 2007). Therefore, we decided to look at the
expression of PD-L1 in CD4+ T cell MLR cultures using WT CD4+ T cells or miR-155deficient T cells. In the first 2 days of the MLR culture there was no difference in PD-L1
expression between WT or miR-155-deficient CD4+ T cells. However, when cultures
were analyzed on day 8 of culture, PD-L1 was significantly increased in the miR-155deficient CD4+ T cells, both in percentage of cells expressing PD-L1 and expression on a
per cell basis (Figure 4.5, B and C). We also looked at the expression of one receptor for
PD-L1 signaling, PD-1. We found that PD-1 expression is significantly decreased in
miR-155-deficient CD4+ T cells, however the percentage of cells expressing PD-1 is not
decreased. (Figure 4.5, C and D). This would suggest that miR-155 regulates expression
of PD-L1 in CD4+ cells, and this regulation may also change the expression of PD-1 on
CD4+ T cells.
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4.2.6 AA mice induced with miR-155-/- splenocytes have a higher absolute number
of iTregs in the spleen and bone marrow compared to WT AA mice

PD-L1 engagement of its receptors on naïve T cells promotes iTreg development
by inhibiting mTOR/Akt signaling (Francisco et al., 2009). Additionally, PD-L1:PD-1
signaling can be used in a humanized GVHD model to convert human Th1 cells into
iTregs in vivo (Amarnath et al., 2011). Therefore, we wanted to see if AA mice induced
with miR-155-deficient cells had an increased number of iTreg cells. To do this, we
induced mice with AA as described above and used flow cytometry to assess the iTreg
population (CD4+CD25+FoxP3+) in the bone marrow and spleen. When we looked at the
percentages of iTregs, there was no difference between WT and miR-155-/- induced AA
mice in the bone marrow (Figure 4.6A) or the spleen (Figure 4.6C). However, there was a
significant increase of iTreg cells in miR-155-/- AA mice when we examined the absolute
number of iTreg cells. AA mice induced with miR-155 deficient cells had significantly
higher absolute numbers of iTreg cells compared to WT AA mice in both the bone
marrow (Figure 4.6B) and the spleen (Figure 4.6D). These results show that miR-155
deficient AA mice have higher numbers of iTreg cells which could be due to the
increased PD-L1 expression on the CD4+ T cells.

4.3 Discussion

Here we show that miR-155 levels are elevated in mice induced with Aplastic
Anemia, and miR-155 is necessary for the development of immunopathogenic T cells
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that drive disease symptoms. miR-155 can decrease the levels of activated Notch1IC both
in vitro after T cell stimulation and in our mouse model of disease, and inhibiting the
activation of Notch using GSI decreases miR-155 levels in CD4+ T cells. We have
identified PD-L1 as a potential target for miR-155 in CD4+ T cells; when miR-155 is
genetically deleted in these cells, PD-L1 expression is increased. In our mouse model,
miR-155-deficient AA mice have an increased number of iTreg cells in both the spleen
and bone marrow, perhaps a result of an increase of PD-L1 expression.
miR-155 expression has been shown to upregulated in human diseases that have a
strong Th1 component, such as multiple sclerosis, rheumatoid arthritis, and atopic
dermatitis when samples are compared to healthy donors (Junker et al., 2009; Sonkoly et
al., 2010; Stanczyk et al., 2008). Therefore, it was not surprising that we had elevated
levels of miR-155 expressed in the bone marrow and spleen of our AA mice. However,
we expected to see a larger difference in levels of miR-155 between our AA patients and
healthy controls. The fact that we didn’t see an increase in patient samples is probably
due to our limited sample size, and our lack of knowledge about the patient’s disease
status. It has been shown previously that expression of markers of Th1 cells, such as TBET often correlate with disease severity and an inability to know the disease severity of
our patient samples could skew our results (Solomou et al., 2006). Also, miR-155 have
been found in exosomes of human saliva and serum (Bala et al., 2012). We may find a
higher expression of miR-155 in different types of patient samples, beyond the peripheral
blood samples we have been analyzing. Moving forward, having a larger patient cohort
with different types of samples may be able to show if there is a true difference in miR155 expression in AA patients.
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Mice deficient in miR-155 do not develop EAE or collagen-induced arthritis, two
autoimmune disease with strong Th1 elements (Bluml et al., 2011; Hu et al., 2013;
O'Connell et al., 2010; Yao et al., 2012). We were pleased to see that miR-155 was also
necessary for AA pathogenesis in our model. Not only were symptoms ameliorated and T
cells that infiltration into the bone marrow ablated, mice induced with miR-155-deficient
splenocytes were able to survive indefinitely. This evidence points to a T cell intrinsic
role that miR-155 is playing in AA. miR-155 has been shown to mediate the
inflammatory affects of CD4+ cells in a mouse model of EAE, and miR-155 deficient
CD8+ cells were ineffective at controlling tumor growth (Dudda et al., 2013; O'Connell et
al., 2010). Further investigation into the role of miR-155 in both CD4+ T cells and CD8+
T cells in our model would be interesting.
We observed that miR-155 deficiency results in a decrease of Notch1 activation in
T cells, both in vitro and in vivo. Also, in MLR cultures, using GSI to inhibit Notch
activation reduces the miR-155 expression in CD4+ T cells. Although neither of these
experiments address direct regulation, it does seem that both of these pathways work in
tandem after T cell activation. Currently, there has been no studies that investigate the
regulation of miR-155 by Notch, or visa versa. However, both Notch1 activation and
miR-155 expression have been shown to be regulated by the NF-κB pathway. While there
have been studies providing a link between the Notch1 and NF-κB signaling pathway in
T cells (Shin et al., 2006; Shin et al., 2014), the studies linking miR-155 expression and
NF-κB signaling has been done only in B cells and cancer cell lines (Ma et al., 2011).
Therefore, it would be interesting to further understand if Notch and miR-155 work
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together to regulate signaling downstream of the TCR and if they interact with NF-κB
signaling to do so.
We next aimed to find a direct mRNA target of miR-155 repression that could be
playing a role in Aplastic Anemia. Upon searching the microRNA target database, Target
Scan, we were able to identify CD274 or PD-L1 as a potential target. Since PD-L1
signaling acts to suppress aberrant T cell activation through interaction with PD-1 or
CD80 (Butte et al., 2007), we reasoned that high miR-155 expression in AA would lead
to a decrease in PD-L1 expression, thus favoring pathogenic T cell activation. We were
able to show that miR-155-deficient CD4+ T cells have increased levels of PD-L1
compared to WT CD4+ T cells. More analysis has to be done into if PD-L1 is a direct
target of miR-155, i.e. does miR-155 directly bind to PD-L1 mRNA on its 3’ UTR
regions to block translation. However, a study pulling down complexes of miR-155 and
Argonaute in CD4+ T cells was able to identify PD-L1 mRNA present in these complexes
(Loeb et al., 2012).
Since PD-L1 engagement of its receptors on naïve T cells promotes iTreg
development, and PD-L1:PD-1 signaling can be used in a human-into-mouse GVHD
model to convert human Th1 cells into iTregs in vivo (Amarnath et al., 2011; Francisco et
al., 2009), we hypothesized that miR-155-deficient AA mice could have higher iTreg
populations in their bone marrow and spleen compared to WT AA mice. While we did
not see a difference in the percentage of iTreg cells, there was a significant difference in
the absolute numbers of iTregs in the bone marrow and spleen of miR-155-deficient AA
mice. To show that higher PD-L1 expression is necessary for iTreg development that in
turn could be ameliorating disease in AA mice, blocking PD-L1 expression in miR-155-
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deficient AA mice and assessing both iTreg populations and disease symtoms should be
performed. Also, further exploration into the kinetics of PD-L1 expression in AA mice
would be helpful in understanding if PD-L1 signaling is turning already differentiated
Th1 cells into iTreg cells in our model, or if miR-155 deficiency is influencing naïve T
cells to differentiate to iTreg cells instead of Th1 cells. All together, this cumulative
evidence shows that miR-155 is important in AA pathogenesis and is functioning, at least
in part, through a repression of PD-L1 expression.
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Figure 4.1 miR-155 expression in mice with Aplastic Anemia is higher compared to
irradiated controls
Mice sub-lethally irradiated only (IR control) or mice induced with AA (BMF) were
harvested on day 17 post disease induction. (A) Whole bone marrow from IR controls
and BMF mice or (B) CD4+ and CD8+ positively selected cells from IR controls and
whole splenocytes from BMF mice were analyzed for miR-155 expression with sno202
used as a reference gene. n=7; Mean + SEM of three independent experiments. (C) CD4+
and CD8+ cells were positively selected from human PBMC (Control) and whole AA
peripheral blood samples (AA Patient Samples) were analyzed for miR-155 using qRTPCR with RPS9 used as a reference gene. n=3; line represents mean of two independent
experiments. *p<0.05, **p<0.01, ***p<0.001; unpaired student t test.
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Figure 4.2 Inducing BMF mice with miR-155-deficient splenocytes ameliorates
disease symptoms
Mice were induced with AA using WT or miR-155-deficient splenocytes. On day 17
post-induction, mice were harvested and (A) total bone marrow cellularity was
determined using trypan blue exclusion. Circulating (B) white blood cells (WBC) and (C)
red blood cells (RBC) were measured. Percentages of (D) CD4+ and (E) CD8+ T cells
infiltrating the bone marrow were determined using flow cytometry. (E) Kaplan–Meier
survival estimates of AA mice induced with disease and treated with WT (n=4) or miR155-deficient splenocytes (n=7; p<0.01) Data are the mean plus SEM and analyzed using
one way ANOVA plus Tukey post test or log rank test for survival estimates *, P < 0.05;
**, P < 0.01; ***, P < 0.001
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Figure 4.3 miR-155-/- AA mice express less Notch1IC in the T cells in the bone
marrow and spleen
Notch1IC was analyzed using flow cytometry in mice induced with AA using WT (BMF)
or miR-155-deficient splenocytes (miR-155 KO), or irradiated only (IR control). Data
represents the Median Fluorescent Intensity (MFI) of Notch1IC in the (A) CD4+ gate (B)
and CD8+ gate of the bone marrow of induced mice and the MFI of Notch1IC in the (C)
CD4+ gate (D) and CD8+ gate of the spleen . n=3-7; Data represents the mean + SEM of
three independent experiments; * p <0.05, ** p<0.01, *** p<0.001; One-Way ANOVA
test with Bonferroni post test.
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Figure 4.4 The expression of intracellular Notch1 in miR-155-deficient CD4+ T cells
is reduced compared to WT CD4+ cells
A mixed lymphocyte reaction (MLR) culture was set up with F1 derivied BMDC cells
mixed with positively selected CD4+ C57BL/6 WT or miR-155-/- cultured for 8 days
Notch1IC expression was analyzed using flow cytometry. (A) Percentage of CD4+ cells
expressing Notch1IC and B) MFI of Notch1IC expression in the CD4 gate are shown. D.
A) WT CD4+ cells were pretreated with DMSO or 50 uM of GSI for 30 minutes and
mixed with F1 derived BMDC in a MLR culture. qRT-PCR was done to determine miR155 expression using sno202 as a reference gene. All expression values were calculated
relative to naïve CD4+ WT T cells. Data are the mean +/- SEM of three independent
experiments. *p<0.05, **p<0.01, ***p<0.001; Two Way ANOVA and Bonferroni post
test.
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Figure 16: Two sites on the 3’ UTR region of the human PD-L1 (CD274) mRNA transcript are complementary to the
seed sequence of hsa-miR-155. A schematic of two predicted complementary sequences of the 3’ UTR PD-L1 mRNA and
miR-155 predict that PD-L1 is a target of miR-155. Red boxes and red text indicate the complementary sequences. The top
sequence is conserved amongst human and mouse (among others), while the bottom is poorly conserved. These sequences
were predicted using the online software, TargetScan (targetscan.org).
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Figure 4.5 PD-L1 expression is increased in miR-155-deficient CD4+cells compared
to WT CD4+cells
(A) A schematic of two predicted miR-155 target sequences on the 3’ UTR PD-L1
mRNA. Red boxes and red text indicate the complementary sequences. The top miR-155
seed sequence is conserved amongst human and mouse (among others), while the bottom
is poorly conserved. These sequences were predicted using the online software,
TargetScan (targetscan.org). (B-E) MLR cultures using WT and miR-155-/- CD4+ cells
were analyzed by flow cytometry. (A) Percent of PD-L1 expression on CD4+ cells, (B)
PD-L1 MFI of CD4+ cells, (C) percentage of CD4+ cells that express PD-1, and D) the
MFI of PD-1 expression on CD4+ cells. Data are the mean +/- SEM of three independent
experiments. *p<0.05, **p<0.01, ***p<0.001; Two Way ANOVA and Bonferroni post
test.
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Figure 4.6 miR-155-deficient AA mice have a more iTreg cells in the bone marrow
and spleen than WT AA mice
Percentage of iTreg expression was analyzed in mice were induced with AA with WT
(BMF) or miR-155-/- (miR-155 KO) splenocytes. iTreg cells were analyzed by FACS
analysis on day 17 post induction and gated as CD4+CD25+FoxP3+ cells. Percentage of
iTreg cells were determined in (A) bone marrow and (C) spleens of induced mice.
Absolute numbers of iTregs were enumerated by multiplying the percentage of iTreg
cells by total cell number of (B) bone marrow and (D) spleen cells. n=3-4. Data are the
mean + SEM of three independent experiments. *p<0.05, **p<0.01, ***p<0.001;
unpaired student t test.
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CHAPTER 5

CONCLUDING REMARKS

Aplastic Anemia is a rare bone marrow failure disease that is characterized by bone
marrow hypoplasia and severe pancytopenia. Fortunately, there is a low incidence of
disease in the United States (less than 6 cases per million population) and the estimated
five year survival rate of those who respond to IST and BMT therapies are 75% and 90%,
respectively (Scheinberg, 2012). However, there is a large cohort of patients who do not
respond to current treatments and eventually succumb to disease.
Understanding the cellular mechanisms that drive AA has long been a focus of
research in the hopes of developing new therapies. Unfortunately, samples from patients
with the disease are rare. Earlier work focused on discovering the epitopes of serum
antibodies and the activating antigen from patient CD8+ T cell clones, but researchers
were never able to pinpoint inciting antigens that caused the vast immune destruction to
the bone marrow in a large cohort of patients (Feng et al., 2004; Goto et al., 2013). It is
possible that inciting antigen in each patient is as diverse as the etiologies of the disease.
However, this could cause difficulty for basic researchers trying to study the disease.
Because an inciting antigen has never been found, the field has had to rely on MHC
haplotype mismatch graft-versus-host disease models for research purposes, and our lab
has been able to develop a mouse model that closely resembles human disease (Roderick
et al., 2013). Using this model, we investigated the involvement of three important
signaling pathways that have been previously implicated in T cell activation and
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differentiation in Aplastic Anemia. First, we are able to show that active PKCθ (pPKCθ)
is highly expressed in our mouse model, and we were able to observe the same high
expression when we looked a pPKCθ levels in patient peripheral blood samples. Previous
studies from our lab have also shown that using PKCθ-deficient donor cells in our mouse
model or treating AA mice with rottlerin, a PKCθ activity inhibitor, ameliorates disease
symptoms (Roderick, unpublished). We were additionally were able to show that PKCθ
acts upstream of Notch1 to drive T cell stimulation and IFNγ production. Since Notch1
signaling is important in AA pathogenesis (Roderick et al., 2013), we can conclude from
this evidence that PKCθ plays an important role in driving Aplastic Anemia and works
upstream of Notch1 to drive disease.
We then investigated the role that NF-κB plays in AA pathogenesis. This works
shows that NF-κB drives AA through multiple mechanisms. In our model, the p50
subunit of NF-κB was needed for the expansion of donor T cells in our model. While
other NF-κB subunits are also important for mediating donor T cell expansion, we did not
have the genetic tools to ask that questions; however, it would be interesting to discern
which subunits were important in T cell expansion during disease. We were also able to
show that NF-κB signaling regulates CXCR4 expression on T cells in our mouse model
and that CXCR4 drives T cells into the bone marrow to mediate destruction. Although
NF-κB has been shown to regulate CXCR4 expression in cancer models (Helbig et al.,
2003), our work is the first to describe direct CXCR4 regulation by NF-κB in T cells and
in Aplastic Anemia.
We finally examined the role of the microRNA, miR-155 in AA. miR-155 is a
microRNA that has been widely implicated in the development and maturation of the
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immune system, and plays a large role in both T cell activation and differentiation. miR155 has been shown to be highly expressed in patient samples from many autoimmune
diseases, and is necessary for the development of these diseases in mouse model studies.
We found that miR-155 is highly expressed in the bone marrow and spleen in our mouse
model, and AA mice induced with miR-155-deficient cells do not develop disease. miR155 regulates Notch1 activation in our AA mice, and although there has been little
research linking these two pathways, both miR-155 and Notch1 have been shown to be
regulated by NF-κB signaling. However, in vitro studies seem to suggest that not only
does miR-155 regulate Notch1 activation, but Notch signaling also regulates miR-155
expression. This could point to the NF-κB as a linker of the two pathways, since Notch
signaling is differentially regulated by NF-κB at different points post TCR activation
(Shin et al., 2006).
We were also able to identify a potential direct target of miR-155 in CD4+ T cells.
PD-L1 was predicted by the database TargetScan.org as a potential direct target of miR155 translational repression, and we were able to show that in CD4+ cells, PD-L1 is
increased when miR-155 is deleted. Further work will have to be done using luciferase
assays to see if the 3’ UTR region of PD-L1 is indeed a direct translational target of miR155. Based on a former study where PD-L1 mRNA could be pulled down with
Argonaute-miR155 complexes in CD4+ T cells, it is a strong possibility that PD-L1 is a
direct target of miR-155 (Loeb et al., 2012). Also, It would also be interesting to if
disease in miR-155-/- AA mice could be rescued by treating mice with a blocking
antibody to PD-L1. This would further confirm that PD-L1 is a target in vivo. Also, it
would be interesting to see if miR-155 regulation of PD-L1 is limited to CD4+ T cells or
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if this regulation is found in other cell types.
The three pathways that are investigated in this work are important to T cell
stimulation, differentiation, and AA pathogenesis. However, it begs the question: would
targeting any of these pathways be a possible therapeutic route for AA? NF-κB and miR155 are pathways that are found to have important roles in many cell types, not just those
of the hematopoietic origin. Therefore, it is possible that targeting these pathways would
not be an improvement on the current IST used for treatment because they would lack
specificity to T cells. In fact, they may be more widely suppressive than current
treatment. More studies into toxicity and off-target affects must be done before any
advancements can be made in these instances.
Targeting the PKCθ pathway, however, could hold more promise. PKCθ expression
is fairly limited to a small amount of cell types, and T cells are the only immune cell in
which PKCθ is expressed. Therefore, inhibiting this pathway could preserve innate
immunity and B cell responses, and in the event that AA patients on PKCθ inhibitors
were also infected with a viral or bacterial pathogen, their other immune responses would
still be able to fight disease. Additionally, PKCθ seems to be selectively needed only in
certain T cell immune responses, further protecting the patient against infectious
pathogens. For example, reports suggest that PKCθ is required for Th2 and Th17
responses, but it has been shown to be dispensable for generating both Th1-mediated
antiviral and memory T cell responses (Kwon et al., 2012; Marsland et al., 2005;
Marsland et al., 2004). Conversely, PKCθ has been shown to play a role in autoimmune
diseases with a strong Th1 component, such as experimental autoimmune
encephalomyelitis, rheumatoid arthritis, and myosin-induced autoimmune myocarditis
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(Healy et al., 2006; Marsland et al., 2007; Salek-Ardakani et al., 2005; Tan et al., 2006).
Also, in a mouse model of graft-versus-host disease (GVHD), PKCθ was required to
induce GVHD pathology, but not to clear viral pathogens or mediate graft-versusleukemia processes (Valenzuela et al., 2009). This evidence is extremely important when
thinking about treatment for AA. PKCθ is clearly necessary in Th1 associated
autoimmune diseases such as AA, however, Th1 responses to intracellular pathogens
seems dispensable, making PKCθ inhibitors very attractive for AA. Maybe most
importantly, PKCθ inhibiting treatments could be used before BMT or in conjunction
with BMT. PKCθ inhibition has been shown to not only block GVHD, but preserve
GVL. This would be an improvement on current therapies, which sometimes cause
rejection of the BMT. For these reasons, PKCθ inhibiting therapies are perhaps the most
compelling in the search for a treatment for refractory and relapsing Aplastic Anemia.
In conclusion, this work investigates multiple pathways that drives the progression
of Aplastic Anemia both in our mouse model and in patient samples. While there is still
much work to be done to elucidate the full story of how these pathways interact to drive
disease, this work presents a strong foundation that can be used in the search for future
therapies.
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CHAPTER 6

MATERIALS AND METHODS

6.1 Animals

All mouse protocols were approved by the Institutional Animal Care and Use
Committee of the University of Massachusetts Amherst. F1 progeny were obtained by
crossing BALB/c females with C57BL/6 males, both obtained from the Jackson
Laboratory (Bar Harbor, Maine). PKCθ-/-, p50-/- and miR155-/- mice were created on a
C57BL/6 background and were maintained as homozygous breeding pairs. PKCθ-/parental strains were originally received as a gift from Dan Littman, and p50-/- and
miR155-/- parental strains were obtained from the Jackson Laboratories. Mice between
the ages of 7–12 weeks were used in experiments.

6.2 Bone Marrow Failure Induction and Analyses

F1 progeny were conditioned with 3 Gy of total body irradiation using a 137Cs
source. 4 to 6 h later, 5 × 107 bulk splenocytes from age- and gender-matched C57BL/6
(WT or knockout) donors were given via i.p. injection. Mice were monitored daily for
signs of disease and harvested on day 17 or 31-post disease induction. For survival
studies, mice were considered lethally induced on the day they were no longer able to
take food or water, at which time they were humanely euthanized. After CO2
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asphyxiation, peripheral blood was obtained via cardiac puncture and sterna were
collected for histology. BM cells were recovered from the tibias and femurs of both legs
by flushing the bones with 5% FBS/PBS. Splenocytes were isolated by manipulation
through a 40-µM filter. Red blood cells were lysed in ACK lysis buffer, and the
remaining white blood cells were enumerated using Trypan Blue exclusion. White and
red cell counts were performed on peripheral blood using a HemaTrue Hematology
Analyzer (Heska).

6.3 In vivo administration of NF-κB inhibitors

For NF-κB inhibition studies, one hour after disease induction mice were treated
with 30 mg/kg/day of DHMEQ or 5 mg/kg/every other day of Bay 11-7085 (Calbiochem,
hereafter abbreviated as Bay 11) administered via i.p. injection and the treatment was
continued until day 16 post-disease induction. Control mice received an equivalent
volume of DMSO vehicle. For NF-κB survival studies, mice were treated with 5
mg/kg/every other day of Bay 11 administered via i.p injection from days 7 to 17 postdisease induction, at which time treatment was discontinued. For survival studies, mice
were considered lethally induced on the day they were no longer able to take food or
water, at which time they were humanely euthanized.

	
  

114	
  

	
  
6.4 Histology

Sterna were harvested on day 17 after BMF induction, fixed in 10% neutral
buffered formalin (VWR) overnight, and decalcified in Cal-Rite (Richard Allen
Scientific) for 48 hours. Samples were preserved in 70% ethanol at 4°C until they were
processed, paraffin-embedded, sectioned, and stained with hematoxylin and eosin.

6.5 T cell isolation and in vitro assays

Spleens were isolated and manipulated through a 40-µM filter (BD Biosciences),
and splenocytes were treated with ACK lysis buffer. CD4+ and CD8+ T cells were then
isolated using the anti-mouse CD4 and CD8 magnetic particles (IMag; BD) and separated
using the BD IMag system. Cells were plated at 2.25–3 × 106 cells/well in 12-well plates
precoated with anti-CD3ε and anti-CD28, purified from 145-2c11 and 37N hybridoma
cell lines, respectively and cross-linked with anti-Hamster IgG (Sigma). Cells were
cultured in a 1:1 ratio of RPMI-1640 and DMEM medium supplemented with 10% FBS
(Gibco), 2 mM l-glutamine, 1 mM Na pyruvate, 100 U/ml penicillin, and 100 µg/ml
streptomycin, at 37°C in a humidified atmosphere with 5% CO2 for the indicated amount
of time. Media and supplements were purchased from Lonza unless otherwise specified.
In some cases, WT T cells cell were treated with DMSO or 3 µM of Rottlerin (Sigma) at
the time of plating or 24 hours after plating, as specified.

	
  

115	
  

	
  
6.6 Patient samples and healthy controls

PBMCs from six patients with severe AA who had not received IST were
obtained from the National Marrow Donor Program Research Sample Repository.
PBMCs from six healthy donors (STEMCELL Technologies) were included as controls.
PBMCs were plated at 106 cells/ml in RPMI 1640 medium supplemented with 10% FBS
(Gibco), 2 mM l-glutamine, 1 mM Na pyruvate, 0.1 mM nonessential amino acids, 100
U/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified atmosphere with 5%
CO2. Media and supplements were purchased from Lonza unless otherwise specified.
Control T cells and AA patient PBMCs were preincubated with DMSO or Rottlerin (3
µM in DMSO) for 30 min at 37°C before being stimulated with 5 µg/ml of plate-bound
anti-CD3ε (UCHT1) and 2.5 µg/ml anti-CD28 (clone 37407) for 48 to 72 h. All
antibodies were purchased from R&D Systems. IFNγ cytokine from supernatants were
determined using a standard ELISA assay (BD Pharmingen).

6.7 Surface and intracellular flow cytometry of murine and human samples

Murine samples were surface stained with PerCP-conjugated anti-CD4 (RM4-5;
BD), Pe-Cy7-conjugated anti-CD8a (53-6.7; eBioscience), and APC-conjugated antiCXCR4 (2B11; eBioscience). For intracellular staining, cells were fixed and
permeabilized using the Foxp3 staining buffer set (eBioscience) and stained with PEconjugated anti-NOTCH1 (mN1A; eBioscience) and PE-conjugated anti-IFNγ (DB-1;
BD) according to the manufacturer’s protocol. For IFNγ staining, cells were harvested
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and cultured in fresh media on anti-CD3ε–coated plates for 5 h in the presence of
Brefeldin A (GolgiPlug; BD).
Human samples were surface-stained with APC–conjugated anti-CD4 (RPA-T4)
and PeCy7–conjugated anti-CD8 (RPA-T8) antibodies. For intracellular staining, cells
were fixed and permeabilized using the Foxp3 staining buffer set (eBioscience) and
stained with PE-conjugated anti-NOTCH1 (mN1A). All human antibodies were
purchased from eBioscience. Samples were acquired on an LSRII flow cytometer and
analyzed using the acquisition software FACSDiva (BD). Analysis of FACS data was
performed using FACSDiva or FlowJo (Tree Star) software.

6.8 Validation of phosphorylated PKCθ detection using flow cytometry

To validate flow cytometric analysis of phospholyated PKCθ, whole cell lysate
were made using RIPA buffer (150mM NaCl, 1% IgeCal-CA 360, 0.1% 619

SDS,

50mM Tris, pH-8.0, 0.5% Sodium deoxycholate) and 40 µg of total protein lysates from
DMSO- or Rottlerin–treated, stimulated murine WT CD4+ and CD8+ T cells was resolved
on an 8% SDS-PAGE, transferred to nitrocellulose, and probed with an anti-p-PKCθ
(Cell Signaling) and anti-actin mAb (AC-40; Sigma-Aldrich) to verify equal loading. The
primary antibodies were detected with HRP-conjugated antibody (GE Healthcare) and
developed using ECL reagents (Amersham). An aliquot of CD4+ and CD8+ T cells from
the same experimental replicate was stained for the surface expression of CD4 or CD8
(described above) and perm/fixed using the BD Cytofix/Cytoperm kit according to
manufactuter’s instructions. Cells were then incubated with anti-pPKCθ (Cell Signaling)
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for 30 minutes, washed, and incubated with Alexa Fluor 488-conjugated anti-rabbit IgG
(Cell Signaling) for 30 minutes. Samples were acquired using an LSRII flow cytometer
as described above.

6.9 Cytometric bead array

Cytokine levels were determined in plasma using either the Th1/Th2 or
Th1/Th2/Th17 cytometric bead array kit (BD) according to the manufacturer’s protocol.
Sample data were acquired on an LSRII flow cytometer and analyzed using FCAP array
software (BD).

6.10 Mixed lymphocyte reaction

To generate BM-derived dendritic cells (BMDC), BM cells from F1 progeny were
cultured at 106 cells/ml in RPMI 1640 medium supplemented with 10% FBS (Gibco), 2
mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 20 ng/ml GM-CFS
(R&D systems), and incubated at 37°C with 5% CO2. On days 2 and 4 post-culture, half
of the media was removed and replaced with fresh supplemented media. On day 6 postculture, non-adherent cells were harvested and cultured in fresh supplemented media for
2 additional days. For the MLR culture, BMDC were co-cultured with bulk splenocytes
from age- and gender-matched WT or KO C57BL/6 mice at a 1:10 ratio in a 1:1 mixture
of RPMI 1640 and DMEM medium supplemented with 10% FBS, 2 mM L-glutamine, 1
mM sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin in 96-well round-
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bottom plates and incubated at 37°C with 7% CO2 for 12 days. To inhibit NF-κB, 1 µM
of Bay 11 or an equivalent volume of DMSO vehicle was added at the time of plating.
From days 6 to 12 post-culture, non adherent cells were harvested every other day and
analyzed for protein expression by flow cytometry or microRNA expression using qPCR.

6.11 Chemotaxis Assay

On day 8 post-culture, non-adherent cells were harvested from the MLR culture to
evaluate their chemotactic response to SDF-1α. Chemotaxis assays were performed in
24-well plate transwell inserts (5 µm polycarbonate membrane, 6.5 mm insert, Corning
Costar) where 600 µl of RPMI 10% FBS with or without 100 ng/ml of SDF-1α (R&D
systems) were added to the plate wells and 0.5 X 106 cells in 0.1 µl of RPMI 10% FBS
were added to the inserts, and incubated at 37°C with 5% CO2. After 3 hours of
incubation, the transwell inserts were carefully removed and the migrated cells were
harvested from the wells. The number of CD4+ and CD8+ T cells was determined by flow
cytometry. The results are expressed as chemotactic index which is the number of
migrated cells from 100 ng/ml SDF-1α wells divided by the number of migrated cells
from 0 ng/ml SDF-1α wells. Media and supplements were obtained from Lonza unless
otherwise specified.
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6.12 mRNA isolation and quantitative real-time PCR

Total RNA was extracted using the RNAqueous kit (Ambion) according to the
manufacturer’s protocol. The RNA (1 µg) was reverse transcribed to cDNA using dNTPs
(Roche), M-MuLV reverse transcriptase reaction buffer (New England Biolabs, Inc.),
oligo-(dT)12–18 (Invitrogen), RNase inhibitor (Promega), and M-MuLV reverse
transcriptase (New England Biolabs, Inc.) on a Mastercycler gradient Thermal Cycler
(Eppendorf). Quantitative real-time PCR was performed in duplicate with SYBR Premix
Ex Taq (Takara Bio Inc.) using the Stratagene Mx3000P qPCR system (Agilent
Technologies). The primer sequences used were: Cxcr4: forward, 5’- GAC TGG CAT
AGT CGG CAA TG -3’; and reverse, 5’-	
  AGA AGG GGA GTG TGA TGA CAA A -3’;
and Actb: forward, 5’- GGC TGT ATT CCC CTC CAT CG -3’, and reverse, 5’- CCA
GTT GGT AAC AAT GCC ATG T -3’. Quantitative real-time PCR conditions were as
follows: 95°C for 1 min, 95°C for 25 s, 62°C for 25 s (35 cycles), 95°C for 1 min, 62°C
for 1 min, and 95°C for 30 s. The relative expression of Cxcr4 was determined using the
2−ΔΔCt method. The results are reported as the fold change in gene expression normalized
to the housekeeping gene Actb and relative to irradiation controls.

6.13 microRNA isolation and quantitative real-time PCR

Total RNA (including microRNA) were isolated using the mirVana Kit (Ambion)
according to manufacturer’s instruction. The RNA (500 ng) was reverse transcribed to
cDNA using dNTPs (Roche), M-MuLV reverse transcriptase reaction buffer (New
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England Biolabs, Inc.), oligo-(dT)12–18 (Invitrogen), RNase inhibitor (Promega), MMuLV reverse transcriptase (New England Biolabs, Inc.) and miR-155 stemp loop primer
GGTTAGACACAAGCGACACTAACCACCCCT on a Mastercycler gradient Thermal
Cycler (Eppendorf). Quantitative real-time PCR was performed in duplicate with SYBR
Premix Ex Taq (Takara Bio Inc.) using the Stratagene Mx3000P qPCR system (Agilent
Technologies). The primer sequences used were: mmu-miR-155-PCR-FW:
GCGGCGTTAATGCTAATTGTG; hsa-mmu-miR-155-PCR-REV:
GCGACACTAACCACCCCTATCQ; hsa-miR-155-PCR-FW:
GCGGCGTTAATGCTAATCGTG; sno202-FW: GCTGTACTGACTTGATGAAAG;
sno202-REV: CATCAGATGGAAAAGGGTTCA; U6-FW:
AGAGCCTGTGGTGTCCG; U6-REV: CATCTTCAAAGCACTTCCCT. Quantitative
real-time PCR conditions were as follows: 95°C for 1 min, 95°C for 25 s, 62°C for 25 s
(35 cycles), 95°C for 1 min, 62°C for 1 min, and 95°C for 30 s. The relative expression of
mir155 was determined using the 2−ΔΔCt method. The results are reported as the fold
change in gene expression normalized to the housekeeping gene sno202 and relative to
controls.

6.14 Statistical analysis

Results are expressed as mean ± SEM. Statistical analysis was performed using
GraphPad Prism 5 (GraphPad Software). P values were calculated using an unpaired twotailed Student’s t -test, one- or two-way ANOVA with post-tests as indicated. Survival
curves were generated using the Kaplan–Meier method and survival differences were
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determined with a Mantel-Cox log-rank test. P values of ≤ 0.05 were considered
statistically significant.
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